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12Searching the new....
INTRODUCTION
Research in the field of pharmaceutical has its most important task in the
development of new better drugs and their successful introduction in to clinical practice.
Communicable diseases account for approximately, one third of all the deaths in the
world according to the WHO report and new drugs and vaccines are urgently needed
both for prevention and treatment of infectious diseases. Central to these efforts,
accordingly stand the search for pharmaceutical substances and preparation which are
new and original. In addition to these objectives, we may search for newer drugs which
exhibit some clear advantages over a drug already known. Such advantages may be
qualitative or quantitative improvement in activity, the absence of undesirable effect,
lower toxicity, improved stability or decreased cost.
Heterocyclic chemistry and medicinal chemistry share a venerable common
history. Many of the founders of heterocyclic systems had an intense intrest not only in
molecules from nature but also in the effects of synthetic compounds on living
systems.There are two main division of medicinal chemistry. The first chemotherapy,
concerns the treatment of infections,parasite or melignant disease by chemical
agents,usually substances that show selective toxicity towards the pathogen. The other
division relates to diseases of bodily difunction and the agents employed are mainly
compounds that effect the functioning of enzymes, the transmission of impluses or the
action of hormones on receptors. Heterocyclic compounds are used for all the
purposes, because they have a specific chemical reactivity. The introduction of
heterocyclic ring in to drugs may effect their physical properties, for example the
dissociation constants of sulpha drugs or modify their patterns of absorption,metabolism
or toxicity.
Medicinal chemistry had its begining when chemist pharmacists and physicians
isolates and purified active principle of plant and animal tissues and latter from micro
organism and their furmentation products. Some of these chemical had been associated
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with therapeutic properties in often it defined disease condition. During the latter
decades of the 20th century, the traditional divinding lines between biological, chemical
and physical sciences were erased, and such as molecular biology, molecular
pharmacology, biomedicine and others began to capture the intrest of medicinal chemistry,
which had learned on the classical field of chemistry, especially organic chemistry, biology
and some area of physics extended new roots in these emerging topics.For many years,
primary sources of information have been delivered in traditional ways, such as books,
journals, patents, encyclopedias, handbooks, dictionaries and literature abstracting and
indexing services. Now the current environment for discovery and development of new
pharmaceutical agent is change. The powerful information system, advanced computer
graphics hardware and software have been developed in last few years. As a result
information is now available in various form of electronic media and also application of
nuclear magnetic resonance and mass spectrometric techniqes to the study of heterocyclic
systems was expanded understanding of the applicability of these methods to variety of
related structural problem.
In addition to scintific and medical issues, the rising expanse of research and
development, the rapidly changing pharmaceutical industry, and the cost pressures on
medical care create other challanges to drug discovery. Overcoming these challenges
through advanced in science and technology that creatively solve problems in infectious
diseases will provide many opportunities for medicinal chemists to advance the antibiotics
field innovatively in to the 21st century.
Heterocyclic compounds show vital role in the field of pharmaceuticals.
Heterocyclic compounds are used because they have a specific clinical reactivity,for
example epoxides, aziridines and β-lactams.With the number of  known organic
compounds approaching five million, more than half of which are heterocyclic and out of
these more than half of heterocyclic system attach with another ring system and give
pharmacological activity.
14Searching the new....
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imigination of organic chemist and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically intresting compounds have
been identified from libraries of widely different composition.
The role of the medicinal chemist is to design a drug structure that has the maximum
beneficial effects with a minimum of side effects. This design has to take into account the
stereoelectronic characteristics of the target active or receptor site and also such factors
as the drug’s stability in situ, its polarity and its  relative solubilities in aqueous media
and lipids. The stereochemistry of the drug is particularly important  because stereoisomers
often have different biological   effects that range from inactive to highly toxic.
AIMS AND OBJECTIVES
In the pharmaceutical field, there have always been and will continue to be a
need for new and novel chemical inhibitors of biological function. Our efforts are
focused on the introduction of chemical diversity in the molecular frame work in order to
synthesizing pharmacologically interesting compounds of widely different composition.
During the course of our research work, looking to the application of hetero-
cyclic compounds, several entities have been designed, generated and characterized
using spectral studies. The details are as under.
♦ To generate several derivatives like 1,3,4-thiadiazolo triazoles, 1,3,4-thiadiazepines,
1,3,4-thiadiazines, azomethines, thiazolidinones, imidazolinone and mannich bases
bearing 1,2,4-triazole nucleus.
♦ To synthesise biologically active 5,6-dihydro-1,3,4-thiadiazolotriazoles
bearing 1,2,4-triazole nucleus using microwave induced synthesis method.
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♦ To genrate different substituted oxopyrimidines, thiopyrimidines and s-methyl
pyrimidines by using MCR (Multi Componant Reaction) concepts.
♦ To check purity of all the compounds using thin layer chromatography.
♦ To characterise these products for stucture elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
♦ To evaluate new products for better drug potential against different strains
of bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37Rv.
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INTRODUCTION
The chemistry of triazole containing compounds have been tremendously
developed and attained greater interest because of its useful applications in medicine,
agriculture and industrial chemistry. Triazole contains three nitrogen atom in five membered
ring system. Triazoles are of two types 1,2,3 triazole (I) and 1,2,4-triazole (II).
The first 1,2,4-triazole derivative was synthesised by Bladin1,2 in 1885. Recently,
much attention has been focused on 1,2,4-triazole derivatives for their broad spectrum
of activities.1,2,4-Triazole derivatives are not only known for their medicinal applications
but also used as analytical reagents3, photographic chemicals4 and in polymer5 synthesis.
SYNTHETIC ASPECTS
Several methods have been reported in the literatures for the preparation of 1,2,4-
triazoles. Some procedures for synthesising 1,2,4-triazoles have been described as under.
1. Kap-Sun Yeung et al.6 synthesised 3,5-disubstituted 1,2,4-triazoles from
nitriles and hydrazides in presence of basic catalyst.
v-Triazole or 1,2,3-Triazole  (I)
R1 C N +
R2
O
NH
NH2
N
N NH
R1 R2
K2CO3, n-BuOH
150 C
(III)
N
H
N
N
N
NH
N
N
H
N
N
N
N
H
N
N
N
NH
s-Triazole or 1,2,4-Triazole   (II)
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2. Ahamad S. Shawali et al.7 synthesised 1,2-bis (4-amino-5-mercapto-4H-
1,2,4-triazol-3-yl) ethane by heating succinic acid with two molar equivalents
of carbonothioic dihydrazide in an oil bath at 170oC.
3. Zhang Zivi et al .8 prepared 1,2,4-triazoles by the addition reaction of
2,4-dichlorophenoxy acetic acidhydrazide with R-CO-NCS gave aroyl
thiosemicarbazides, cyclization of this in H2O in the presence of alkaline
catalyst gives triazoles.
4. Reid and Heindel9 reported that the reaction of aryl acidhydrazide with
CS2/KOH and hydrazine hydrate furnished triazoles.
5. Shin-ichi Nagai10 synthesised triazole by the reaction of thiosemicarbazide
with formic acid in presence of acetic anhydride.
6. C. S. Andotra and Sukhbinder Kaur11 synthesised triazolopyrimidine by
the reaction of aromatic acid with substituted hydrazino pyrimidine.
HOOC
COOH
+
NH2
NH NH
NH2
S
-4H2O
N
N
N
H
N
H
N
N
NH2
S
S
NH2
2
(IV)
O
NH
NH
NH
R
O
S
O
ClCl
N N
N
O
ClCl
SH
O
R
alkaline catalyst
(V)
R
O
NH
NH2
CS2
KOH
R
O
NH
NH
S
S K
- + NH2.NH2.H2O
N
N N
NH2
R SH
(VI)
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THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good activity
are listed as under..
N
N
NH
NH2
R
R1
N
N
N
N
R
R1
R2
R2
O
OH
(VII)
CH3
O
O
N
NN
Cl
Cl
Propiconazole
NN
N
O
OH
OHOH
NH2 O
Rifavirin
Antifungal Antiviral, Antiinfections
N
N
N
N
NH2
O
CH3
N
N N
CH3 CH3NC
CH3
CH3
NC
Bemitradine
Diuretics
Anastrozole
Antineoplastic
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N
N
N
NN
Letrozole
Antineoplastic
N
N
N
O
Cl
Cl
N CH3
CH3
O
Rilmazafone
Sedative, Hypnotic
Sn N
N
N
Azocyclotin
Pesticide
NNH
N
NH2
Amitrole
Antithyroid activity
N
N
NH O
O N N N
N
N
CH3
OH
CH3
F
F
O
Posaconazole
Antifungal
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According to literature survey various 1,2,4-triazole derivatives have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological activities.
Therapeutic activity of 1,2,4-triazoles are listed as under.
1.  Antiviral12
2.  Anticonvulsant13
3.  Anticancer14
4.  Antimicrobial15
5.  Anti-inflammatory16,17
6.  Antihypertensive18
7.  Antileishmanial19
8.  Antidepressant & Anxiolytic20,21
9.  Antitumor22
10. Anthelmintics23
11. Bactericidal24
12. Diuretic25
13. Fungicidal26
14. Herbicidal27
15. Insecticidal & Acaricidal28
16. Plant growth regulator29
17. Antiarthritic30
 Daniele Bianchi et al.31 have screened pure stereoisomer of two new triazole
derivatives (X,XI) for their antifungal activity against variety of  fungi showing an activity
ratio R-form/S-form upto 400.
OH
N
N
N
Cl
Cl
OCF2CHF2
N
N
N
Cl
Cl (XI)(X)
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L.Z.Xu and co-workers32 have synthesised an important class of triazole
derivatives (XII) which are highly efficient low poisonous and inward absorbent33-35
and studied their antifungal activity. Dawei Cui et al.36 have prepared some new triazoles
(XIII) and reported them as significant antifungal agent.
M.Dincer et al.37 have synthesised triazole derivatives (IVX) as potential
antimicrobial agent. L.H.Mackendry and co-workers38 have investigated triazole
derivatives (XV) and reported them as broad spectrum broadleaf herbicides.
Andreina Liendo et al.39 have discovered both enantiomers of 2-(2,4-
difluorophenyl)-1-[3-(z)-4-(2,2,3,3-tetrafluoropropoxy)styryl]-12,3-triazole-1-yl)-3-
propane-2-ol. It has recently been shown that the R(+) enatiomer of bis triazole
derivatives (XVI) can induce radical parasitological cure in marine mouldes of the acute
and chronic forms of the disease.
N
N
N
S
O
R
R1
R2
S
N
NN
NH S
S
CH3
NH
R1 R2
R3
(XIII)(XII)
N N
N
NH
Cl Cl
CH3
N
N N
N
EtO
FSO2
NH
ClCl
(XV)(IVX)
N
N
N
N
N
N
O
CF2 CHF2
(XVI)
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Yaseen A. et. al.40 have prepared 1,5-dialkyl-3-(5-mercapto-4,N-aryl-1H-
1,2,4-triazol-3-yl-methylene)-1H-1,2,4-triazole which exhibited remarkable activity
against nine type of cancer and also antiviral activity. Bignon Eric et. al.41 have reported
N-triazolyl-2-indole carboxamides and their use as CCK-A agonists. These compounds
have partial or total CCK-A receptor agonist activity and are useful for treating eating
problem, obesity, tardive dyskinesia and disorders of the gastrointestinal sphere (XVII).
Ilkay Kricukguzel et al.42 have formulated some new triazole derivatives
possessing anticonvulsant activity. Neslihan Demirbas et. al.43 have screened triazole
derivatives for their antiinflammatory, anticancer, antituberculosis and antihypertensive
acitivities.Veru Klimesova et al.44 have reported 1,2,4-triazoles useful for tuberculosis
inhibition. B. Shivarama Holla et al.45 have investigated some triazole derivatives as
anticancer agent. Liu Chanjian et al.46 have investigated triazoles (XVIII) as IMPDH
inhibitors. Neslihan Demirbas and his co-workers47 have documented antimicrobial
activity of some newly synthesised 1,2,4-triazole derivatives. L. Labanauskas et. al.48
have documented antiinflammatory activity of some triazoles.
Recently, Dae-Kee Kim et. al.49 have synthesised 1,2,4-triazole derivatives and
screened for their significant ALKS inhibitory activity in the luciferase reporter assays.
Abbas Shafiee and co-workers50 have synthesised 1,2,4-triazole derivatives (XIX) and
screened for their antibacterial activity.
N
N
N
N
NH
NH2
O
N
OCH3
(XVIII)
N
N N
NH C
O N
R'
R
R'
(XVII)
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 Marie-Odile Contour-Galcera et. al.51 have synthesised 3-thio-1,2,4-
triazoles(XX) and reported as non-peptidic human somatostatin receptor subtypes
2 and 5 agonists. K.M.Basavaraja and co-workers52 have prepared triazole
derivatives(XXI) and reported their antibacterial activity. Nawal A.El-Koussi et. al.53
have prepared a series of 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic acid
derivatives. Some of the compounds were found to be equipotent or more potent than
Indomethacin and Celecoxib as reference drugs at two dose levels, 5 and 10 mg/kg, and
they have no ulcerogenic activity. Synthesis and antioxidant activities of some
4-benzylidenamino- 4,5-dihydro-1H-1,2,4-triazol-5-one derivatives has been investigated
by Haydar Yuksek et. al.54.
Thus, the important role displayed by 1,2,4-triazole nucleus for various
therapeutic activities prompted us to synthesise 1,3,4-thiadiazolotriazoles, 1,3,4-
thiadiazepines, 1,3,4-thiadiazines, azomethines, thiazolidinones, imidazolinones, nitriles
and Mannich bases bearing 1,2,4-triazole nucleus, which have been described as under.
[A] STUDIES ON TRIAZOLES
PART-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZOLOTRIAZOLES
PART-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZEPINES
S
O SMe
N
N
N R1
R
(XIX)
N N
N
O O
R
R'
N
NN
S
R3
R1
R2
(XX) (XXI)
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PART-III  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZINES
PART-IV  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
 AZOMETHINE DERIVATIVES
PART-V  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
MANNICH BASES
PART-VI  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
 IMIDAZOLINONES
PART-VII  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
 NITRILES
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INTRODUCTION
1,3,4-Thiadiazole derivatives have been extensively explored for their importance
in the field of pharmaceutical development. This five membered heterocyclic ring has
attracted attention world wide, having one sulphur and two nitrogen atoms. Thiadiazole
ring system with three hetero atoms does not exhibit tautomerism in its fully conjugated
form. However, when certain substituents are present tautomerism is possible. According
to the position of nitrogen  and sulphur atoms, they are classified as 1,2,3-thiadiazole
(I ), 1,2,4-thiadiazole (II), 1,3,4-thiadiazole (III) and 1,2,5-thiadiazole (IV).
In 1882, Fischer first suggested 1,3,4-thiadiazole and further developed by Busch
and co-workers. The compounds having thiadiazole nucleus have stimulated considerable
research work in recent years, leading to the synthetic utility of the derivatives of this
ring system.
SYNTHETIC ASPECTS
Various publications and patents55  for the preparation of 1,3,4-thiadiazoles have
been cited in literature.
1. Ahmad  M Farag et al.56 have suggested one step synthesis of thiadiazole
derivative. N-N’-Diaryloxalodihydrazonyl dihalides reacts with potassium
thiocyanate or thiourea and yield the thiadiazole derivative.
S
N
N
S
N
N
S
N N
S
N N
(I) (II) (III) (IV)
N
N NH
NH X
X
Ar
Ar
KCNS
S
N N
S
N N
Ar
NH
NH
Ar
(V)
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2. M.K. Albrahim et al.57 synthesised  thiadiazole from hydrazinyl chloride.
3. Li-Xue Zhang et al.58 have synthesised 1,3,4-thiadiazoles by the cyclisation of
aromatic acid with triazole in presence of catalyst like POCl3.
4. Alla Hassan et al.59 prepared thiadiazole by the cyclisation of tetracyano ethene
and 4-phenyl thiosemicarbazides.
5. Z.Kaleta et al.60 synthesised novel thiadiazole derivatives by the use of  fluorous
Lawesson’s reagent.
N N
N
NH2
O
SH
POCl3
Ar-COOH
N N
N
O
S
Ar
(VII)
N
NH
NH N
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Cl R
R
R N
NH
N
N S
NH CO
R'
COCH3
R'-CO-NCS
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NH NH
NH2
S
+
N
NN
N S
N N
N
N
RHN
(VIII)
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NH
R
O
R
O
S
P
S
P
S
S Ar
Ar
1 eq. F. Lawesson's Reagent
THF, 55 C, 17 hrs
S
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RAr
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THERAPEUTIC IMPORTANCE
1,3,4-Thiadiazole derivatives exhibit broad spectrum of therapeutic activity.
Several biological activities associated  with thiadiazole have been described as under.
1. Antibacterial61
2. Amoebicidal62
3. Antagonist agent63
4. Antitumor64
5. Antitubercular65
6. Pesticidal66
7. CNS depressant67
8. Hypoglycemic68
9. Antiviral69
10. Antipyretic70
11. Anthelmintic71
12. Antiallergic72
13. Antihypertensive73
14. Anticonvulsant74
15. Insecticidal75
Gundurao Kolavi et al.76 have prepared new imidathiadiazole derivatives (X),
which act as powerful antitubercular agents with 100% inhibitory activity (MIC > 6.25 µg/ml).
Clerici F.et al.77 have synthesised and screened 1,3,4 thiadiazoles for their antidepressant
and anxiolytic activity. The purpose of this study was to evaluate the effect of the
compounds on CNS activity by varying the substituents  in the thiadiazole moiety. It was
found that some compounds possess marked antidepressant and anxiolytic activity
comparable in efficiency to the reference drug Imipramine.
O
N
S
N
N
CHO
S
N N
N
O
R
F
O
NHCOCH3(X) (XI)
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Erhan Palaska et al.78 investigated some thiadiazoles possessing anti-inflammatory
activity. Lisa M. Thomasco et al.79 have first synthesised morpholine derivative then
replacement of morpholine ring with 1,3,4-thiadiazolyl ring (XI) leads to better
antibacterial activity. Nalan Terzioglu et al.80 have documented anticancer activity and
cytotoxicity of 1,3,4-thiadiazoles. Andanappa Gadad et al.81 have prepared thiadiazoles
and reported them as antibacterial agent.
Ishvarsinh Rathod  and co-workers82 have synthesised N-(1,3,4-thiadiazolo-2-
yl)-5-(substituted)-2-amino-4,5-(disubstituted) thiophene-3-carboxylic acids (XII) as
analgesics and  antiinflammatory agent. Samir A. Carvalho et al.83 have synthesised
series of thiadiazole derivative (XIII) From which  a new potent trypanomicide, called
Brazilizone (A) has been identified. Marina Kristanida et al.84 suggested thiadiazoles
and reported them as antiviral agent.
Maarouf AR. et al.85 have synthesised thiadiazole derivatives, which shows
diuretic activity. Kwan-Young Jung and co-worker 86 have devoloped potent and selective
human adenosine A3 receptor antagonists. From all the compounds the most potent A3
receptor antagonists is 4-methoxyphenyl derivative. Jui-Yi-Chou et al.87 have synthesised
several thiadiazole derivatives and examined their cytotoxic effect on human non-small
cell lung cancer A549 cells and found that thiadiazole derivatives are the most effective
one by the MMT assay.
Mohd Amir and Kumar Shikha88 have prepared 1,3,4-thiadiazoles which exhibits
anti-inflammatory, analgesic as well as ulcerogenic activity. Alireza Foroumadi and
co-workers89 have developed thiadiazole derivatives and screened for their
antituberculosis activity. Amir M.et al90 have synthesised thirteen cyclised derivatives
of thiadiazole. Out of  thirteen, eleven screened for their anti-inflammatory activity by
(XII)
N
N
S
N N
NH
N
OH
OH
CH3
O2N
(XIII)
S
NH S
N N
CH3
R1
R2
R
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Winter et al. method and four compounds showed significant activity. These compounds
also inhibit lipid peroxydation in the gastric mucosa and show gastrosparing activity
also. Bernard Masercel et al.91 have discovered some novel thiadiazoles possessing
potent carbonic anhydrase inhibitor properties and also prepared  5-valproylamido 1,3,4-
thiadiazole-2-sulfonamide (IVX), useful as strong anticonvulsant.
Che Chao et al.92 have investigated thiadiazole derivatives and tested for antifungal
and plant growth regulating effect. Andanappa K. Gadad et al.93 have synthesised
compounds of the type (XV) and the selected compounds were evaluated for their
preliminary  in vitro antituberculosis activity against Mycobacterium Tuberculosis H37Rv
strain using radiometric BACTEC and  broth dilution assay method and most of the
compounds exhibited moderate to good activity. Hatice N. Dogan et al.94  have reported
thiadiazole derivatives (XVI-a,b) the degree of protection afforded by these compounds
against PT2-induced convulsion in mice ranged from 0-90%,the compound shows both
anticonvulsant and antimicrobial activity against Gram positive and Gram negative
organism.
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh and co-workers have synthesised 1,3,4-thiadiazoles having
dapsone95,96 bis moiety at 5-position (Y) and benzalamino, benzoylamino and
sulphonamido97, aryl98 moiety substituted at 2-position (X). H. H. Parekh et al.99
have formulated some new thiadiazoles as biologically active agents. Parikh et. al. have
N
S
N
N R3
R2
R1MeHNOC
NH
S
N
SO2NH2 R1 = SO2NH2, CH3
R2 = Br, SCN
R3 = Aryl / Het.(XV)(IVX)
S
N N
NH
R
OH
S
N N
R
OCOCH3
COCH3
(XVI-b)(XVI-a)
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used substituted thiazolidinone100, 4-pyridyl101 moities at 5-position (y) in 1,3,4-
thiadiazole ring system and at 2-position (x) was substituted aryl amino and S-triazine102.
General structure for above references are as under.
Recently, Fathalla O A. et al.103 have investigated thiadiazoles as antifungal agent.
Joanna Matysiak and co-workers104 have discovered the new thiadiazole derivatives
which shows antiproliferative activity. From the series of the compounds 2-(2,4,-
dihydroxyphenyl)-5-(4-methoxy benzyloxy)1,3,4-thiadiazole (XVIII), which exhibits
highest antiproliferative activity against human cancer cell lines. A.A. Aly and R.El-Sayed 105
have screened thiadiazoles for their antibacterial activity. Oruc E.E et al.106 have
synthesised thiadiazole and studied their analgesic activity. R. H. Udipi et. al.107 have
synthesised some new triazolo[1,3,4]-thiadiazole derivatives useful as analgesic and
antiinflammatory agents. Silvia Schenone and co-workers108 have synthesised new 2,4-
disubstituted 1,3,4-thiadiazole derivatives (XIX) which showed analgesic and
antiinflammatory activity, in vivo ulcerogenic action was also reported.
S
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CH3
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NH C O HC N
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In view of the pronounced biological activities of 1,3,4-thiadiazoles, the synthesis
of new derivatives which contain above mentioned pharmacologically active nuclei have
been undertaken.
SECTION-I :SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-(o,p-
DICHLOROPHENYL) -6-ARYL-1,2,4-TRIAZOLO[4,5-b]-1,3,4-
THIADIAZOLES
SECTION-II :SYNTHESIS  AND BIOLOGICAL EVALUATION OF  3 -
  (o,p-DICHLOROPHENYL) -6-ARYLAMINO-1,2,4-TRIAZOLO
  [4,5-b]-1,3,4-THIADIAZOLES
S
S
N
N
O
NH
C
O
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O
(XVIII) (XIX)
S
NN
R
OH
OH
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(o ,p -
DICHLOROPHENYL) -6-ARYL-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLES
Thiadiazole derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of thiadiazole derivatives by the
cyclisation of 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole with  different
aromatic acids  in presence of phosphorous oxychloride.
The structures of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 µg/ml using Rifampin as standard drug.
N N
N
N
S
Cl
R
Cl
        Type - (I)                   R=Aryl
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REACTION SCHEME
        Type - (I)                   R=Aryl
N N
N
NH2
SH
Cl
Cl
O
NH NH2
Cl
Cl
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
N
S
Cl
R
Cl
R-COOH
POCl3
Cl COOH
Cl
Cl COOC2H5
Cl
C2H5OH
Con.H2SO4
NH2.NH2.H2O
CH3OH
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(o,p-DICHLOROPHENYL)-6-(p-METHOXYPHENYL)-
1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2927 2975-2950 430
-CH3 C-H str. (sym.) 2852 2880-2860  “
C-H i.p.def. (asym.) 1458 1470-1435  “
C-H o.o.p. def. (sym.) 1373 1390-1370  “
Aromatic C-H  str. 3122 3080-3030 431
C=C str. 1564 1585-1480  “
C-H i.p. def. 1103 1125-1090  “
C-H o.o.p. def 813  835-810  “
Triazole C=N str. 1602 1612-1593 430
moiety C-N str. 1317 1350-1200 434
N-N str. 1024 1050-1010 430
C-Cl str. 732  600-800 432
Ether C-O-C str. (asym.) 1255 1275-1200 430
C-O-C str. (sym.) 1024 1075-1020  “
                                              (overlapped)
Thiadiazole C-S-C str. 698                      720-570 434
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 698.2
 732.9
 813.9
 866.0
 941.2
 968.2
1024.1
1043.4
1103.2
1147.6
1166.9
1255.6
1317.3
1334.6
1373.2
1421.4
1458.1
1508.2
1564.2
1602.7
2852.5
2927.7
3122.5
3296.1
N
N
N
N
S
O
CH3
Cl
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-(o ,p -DICHLOROPHENYL)-6- (p -
METHOXYPHENYL)-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.89 3H singlet Ar-OCH3     -
2. 6.99-7.02 2H doublet Ar-Hee’ Jde=8.79
3. 7.81-7.84 2H doublet Ar-Hdd’ Jed=8.84
4. 7.76-7.79 1H doublet Ar-Ha  Jab=8.44
5. 7.43-7.46 1H double Ar-Hb      -
doublet
6. 761-7.62 1H doublet Ar-Hc Jcb=2.10
N N
N
N
S
Cl
OCH3
Cl
a
b
c
d
e
d'
e'
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EXPANDED AROMATIC REGION
N N
N
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S
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OCH 3
Cl
N N
N
N
S
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OCH3
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c
d
e
d'
e'
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-(o,p- DICHLOROPHENYL)
-6-ARYL-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Ethyl-2,4-dichlorobenzoate109
A mixture of 2,4-dichlorobenzoic acid (1.90 g, 0.01M) in ethanol (20 ml) and
con. H2SO4 (1 ml) was refluxed for 16 hrs. The reaction mixture was poured into ice
cold water. The product was isolated and crystallised from ethanol. Yield 85%, m.p.
135oC.
(B) Synthesis of 2,4-Dichlorobenzoic acidhydrazide109
A mixture of ethyl-2,4-dichlorobenzoate (2.18 g, 0.01M) in ethanol (20 ml)
and hydrazine hydrate (0.5 g, 0.01M) was refluxed for 5-6 hrs. The reaction mixture was
poured into ice cold water. The product was isolated and crystallised from ethanol.
Yield 85%, m.p. 155oC.
(C) Synthesis of Potassium o, p-dichlorobenzoyl dithiocarbamate
A mixture of potassium hydroxide (0.84 g, 0.015M) in absolute ethanol (25 ml),
2,4-dichlorobenzoic acidhydrazide (2.04 g, 0.01M) and carbon disulfide (1.14ml,
0.015M) was stirred for 24 hrs. The product was precipitated by adding diethyl ether
(50 ml) Yield 92%.
(D) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
A suspension of potassium o, p-dichlorobenzoyl dithiocarbamate (3.26 g, 0.01M),
hydrazine hydrate (95%, 1ml, 0.02M) and water (1 ml) was refluxed with stirring for 8
hrs. The content was diluted with water and acidified with glacial acetic acid to get the
product. It was crystallised from ethanol. Yield 57%, m.p. 185oC, (C8H6Cl2N4S :
required : C, 53.20; H, 2.79; N, 15.51; found : C,53.32;  H, 2.85; N, 15.61%).
TLC solvent system : Acetone : Benzene (4 : 6).
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(E) Synthesis of  3-(o, p-Dichlorophenyl)-6-p-methyl-1,2,4-triazolo[4,5-b]-
1,3,4-thiadiazoles
A mixture of 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01M) and p-methylbenzoic acid(1.36 g, 0.01M) in phosphorous oxychloride
(20 ml) was refluxed  for 10 hrs. It was cooled and poured onto crushed ice and
neutralised with sodium bicarbonate. The product was isolated and crystallised from
ethanol. Yield 58%, m.p. 178oC (C16H10Cl2N4S ; required : C, 50.94; H, 2.67; N,
15.51, found : C, 51.16; H, 2.95; N, 15.63%).
TLC solvent system :  Acetone : Benzene (4 : 6).
Similarly other substituted 1,3,4-thiadiazolo triazole derivatives were
synthesised. The physical data are recorded in Table No. 1.
(F) Antimicrobial activity of  3-(o, p-Dichlorophenyl) -6-aryl-1,2,4-triazolo
[4,5-b]-1,3,4-thiadiazoles
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method56 which
has been described as under.
(G) Antibacterial activity
The purified products were screened for their antibacterial activity. The nutrient
agar broth prepared by the usual method, was inoculated aseptically with 0.5 ml of 24
hrs. old subcultures of B. coccus, S. aureus, E.aerogenes, P. aeruginosa in separate
conical flasks at 40-50oC and mixed well by gentle shaking. About 25ml content of the
flask were poured and evenly spreaded in a petridish (13cm in diameter) and allowed to
set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer in agar
medium and filled with 0.04ml (40mg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also maintained
with 0.04 ml of DMF in a similar manner and the zones of inhibition of the bacterial
growth were measured in millimeter and are recorded in Graphical Chart No.1.
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The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics like amoxicillin, benzoyl penicillin, ciprofloxacin and
erythromycin.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud’s agar slants. Sterilized Sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a separate
f l a sk .  Abou t  25  ml  o f  the  inocu la ted  med ium was  even ly  sp readed  in  a
petridish and allowed to set for two hrs. The cups (10 mm in diameter) were punched
and filled with 0.04 ml (40 µg) solution of sample in DMF. The plates were incubated at
30oC for 48 hrs. After the completion of incubation period, the zones of inhibition
of growth in the form of  diameter in mm was measured. Along the test solution in each
petridish one cup was filled with solvent which act as control. The zones of inhibition
were compared with standard antifungal Greseofulvin. The zones of inhibition are recorded
in Graphical Chart No. 1.
(b)Antitubercular activity
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition and Co-ordination Facility (TAACF), U.S.A. Primary screening
of the compounds for the antitubercular activity have been conducted at 6.25 µg/ml
towards Mycobacterium tuberculosis H37Rv in BACTEC 12B using the BACTEC
460 radiometric system. The compounds demonstrating atleast>90% inhibition in the
primary screening has been tested at lower concentration towards Mycobacterium
tuberculosis H37Rv to determine the actual minimum inhibitory concentration (MIC)
in the BACTEC-460.
The antitubercular activity data have been compared with standard drug Rifampin
at 0.25 µg/ml concentration and it showed 98% inhibition.
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate110
Gram positive bacteria : Bacillus coccus
Staphylococcus aureus
Gram negative bacteria : Enterobacter aerogenes
Pseudomonas aeruginosa
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoyl penicillin,
Ciprofloxacin, Erythromycin
Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Benzoyl penicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared
with viz Greseofulvin. The inhibition zones measured in mm.
       ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : : 6.25 µg/ml.
Standard drug: : Rifampin.
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Dr. H. H. Parekh
CONCLUSION
ANTIBACTERIAL ACTIVITY
From the exeperimental data it has been observed that the compound bearing
R=4-methoxyphenyl have displayed considerable activity (20mm) against B.coccus. The
compounds  bearing R=2-methylphenyl, 4-nitrophenyl and 4-hydroxyphenyl have
shown maximum activity against  S. aureus.
In case of Gram negative bacterial strain maximum activity was observed in
compounds bearing R = 4-aminophenyl and pyridine nucleus have fairly inhibited the
growth of E.aerogenes. All the compounds were slightly active against  P.aeruginosa.
While the compound bearing R=4-aminophenylhave displayed significant activity (23mm).
ANTIFUNGAL ACTIVITY
All the compounds are found to be active against A. niger. Maximum activity
was shown by the  compounds bear ing R=4-hydroxyphenyl  (21mm) and
R=4-methylphenyl (20mm).
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & greseofulvin.
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TABLE NO. 1a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
N N
N
N
S
R
Cl
Cl
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID Comment
Assay
295421 ALP-13 4-OCH3-C6H4- Alamar H37Rv >6.25 0 - MIC Rifampin =
  0.25 mg/ml
@ 98% Inhibition
295422 ALP-14 4-CH3-C6H4- Alamar H37Rv >6.25 09 - "
295423 ALP-15 2-CH3-C6H4- Alamar H37Rv >6.25 22 - "
295424 ALP-16 4-Br-C6H4- Alamar H37Rv >6.25 24 - "
295425 ALP-17 2-NO2-C6H4 Alamar H37Rv >6.25 09 - "
295426 ALP-18 -C2H2-C6H5 Alamar H37Rv >6.25 0 - "
295427 ALP-19 C5H4N- Alamar H37Rv >6.25 0 - "
295428 ALP-20 4-OH-C6H4- Alamar H37Rv >6.25 0 - "
295429 ALP-21 2-Cl-C6H4- Alamar H37Rv >6.25 0 - "
295430 ALP-22 2,4-(Cl)2-C6H3- Alamar H37Rv >6.25 0 - "
MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-(o,p- DICHLOROPHENYL)
-6-ARYL AMINO-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLES
Amino thiadiazole are endowed with various biological activities. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was considered
worthwhile to synthesise some new amino thiadiazoles bearing triazole nucleus. The
preparation of 3-(o,p-dichlorophenyl)-6-aryl amino-[1,2,4]triazolo  [4,5-b][1,3,4] thiadiazoles
(II) have been undertaken by cyclocondensation of 3-mercapto-4,N-amino-5-
(o,p-dichlorophenyl)-1,2,4-triazole with  different aryl isothiocyanates in DMF.
The structures of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Type (II)       R = Aryl
N N
N
N
S
Cl
Cl
NH R
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REACTION SCHEME
        Type - (II)                   R=Aryl
N N
N
NH2
SH
Cl
Cl
O
NH NH2
Cl
Cl
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
N
S
Cl
Cl
NH R
R-N=C=S
DMF , K2CO3
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(o ,p -DICHLOROPHENYL)-6-(p-METHYLPHENYL)
AMINO-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2931 2975-2950 430
-CH3 C-H str. (sym.) 2862 2880-2860  “
C-H i.p.def. (asym.) 1460 1470-1435  “
C-H o.o.p. def. (sym.) 1373 1390-1370  “
Aromatic C-H  str. 3089 3080-3030  431
C=C str. 1562 1585-1480  “
C-H i.p. def. 1101 1125-1090  “
C-H o.o.p. def  813  835-810  “
Triazole C=N str. 1633 1640-1605 434
moiety C-N str. 1232 1350-1200 “
N-N str. 1045 1050-1010 430
C-Cl str. 736 600-800 432
Thiadiazole C-S-C str. 646  720-570 433
Amino -NH str. 3365 3450-3200 430
-NH def. 1604 1650-1580  “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 478.3
 569.0
 623.0
 646.1
 736.8
 813.9
 866.0
 950.8
1008.7
1045.3
1101.3
1145.6
1232.4
1373.2
1460.0
1490.9
1562.2
1604.7
1633.6
2862.2
2931.6
3089.8
3365.6
N
N
N N
S
Cl
Cl
NH
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 3-(o,p-DICHLOROPHENYL)-6-(p-METHYPHENYL) AMINO-
1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 2.32 3H singlet Ar-CH3              -
2. 7.13-7.16 2H doublet Ar-Hee’ Jde-8.28
3. 7.41-7.43 2H doublet Ar-Hdd’ Jde-8.48
4. 7.46-7.47 1H double Ar-Hb -
    doublet
5. 7.624-7.629 1H doublet Ar-Hc Jcb-2.00
6. 7.77-7.79 1H doublet Ar-Ha Jed-8.40
7. 10.41 1H singlet -NHf -
a
b
c
d
e
d'
e'
N
N
N
N
S
Cl
Cl
NH
CH3
f
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EXPANDED AROMATIC REGION
N
N
N
N
S
Cl
Cl
NH
CH3
a
b
c
d
e
d'
e'
f
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(o,p- DICHLOROPHENYL)
-6-ARYL AMINO-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Potassium o, p-dichlorobenzoyl dithiocarbamate
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of Phenyl isothiocyanate.
 Ammonia solution (90 ml,0.88 M) is taken in three neck flask and cooled. Then
54gm (43 ml, 0.71 M) of CS2 is added  and stirr the solution. Now, 56 gm(55 ml, 0.60 M)
aniline is added from seperatory funnel. A heavy precip i tate  of  ammonium
phenyldithiocarbamates is seperated. Salt is transfered and pour it in 200ml of water.
Resulting solution is added  in to 200gm (0.60 M) of lead nitrate in 400ml of water
with constant stirring and finaly isolated the product with steam distillation.
(D) Synthesis of 3-(o,p-Dichlorophenyl)-6-methylphenyl -amino-[1,2,4]triazolo
[4,5-b][1,3,4]thiadiazole
A mixture of  3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01M), p-methylphenyl isothiocyanate (1.49 g, 0.01 M) in DMF (40 ml)  and
anhydrous pottasium carbonate was stirred  for 8 hrs at 70-80oC. Then the reaction
mixture was poured on to crushed ice. The precipitated solid  was filtered, washed with
water and crystllised from  DMF. Yield 62%, m.p. 168oC (C16H11Cl2N5S;   Required
: C,51.07; H, 2.95 N, 18.58  Found : C, 51.19; H, 3.05; N, 18.70%).
TLC solvent system : Ethyl acetate  : Hexane (3 : 7).
Similarly other aryl isothiocyanates have been condensed. The physical data are
recorded in Table No. 2.
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(E) Antimicrobial activity of  3-(o,p-Dichlorophenyl)-6-aryl amino-[1,2,4]triazolo
[4,5-b][1,3,4]thiadiazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 2.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of amino thiadiazoles (type-II) revealed that all the
compounds were able to inhibit the growth of Gram positive & Gram negative bacterial
strains.
In case of Gram positive bacterial strain, maximum activity was observed in
compounds bearing R =3-chlorophenyl and 2,3-dimethylphenyl against B. coccus. The
significant activity was displayed by compounds having R=4-methoxyphenyl, 2-chloro, 5-
methylphenyl and 2-methoxyphenyl  against S. aureus.
In case of Gram negative bacterial strain,compounds containing halogen group
as substituent like R=3-chlorophenyl and 4-chlorophenyl  have fairly inhibit the growth
of E.aerogenes. Almost all compounds were found mildly active but the compounds
bearing R= 4-methylphenyl and 2-nitrophenyl displayed significant activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
 Compound having R=2-methoxyphenyl, 2-nitrophenyl and 2-methylphenyl  have
shown better activity against A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz.greseofulvin.

57Thiadiazepines....
INTRODUCTION
The thiadiazepine ring system have one sulphur atom and two nitrogen atoms at
1,3,4-position (I) in seven membered heterocyclic ring system.Chemical properties of
1,3,4-thiadiazepine derivatives have been reviewed in the last few years. However the
usefulness of thiadiazepine as a previledged system in medicinal chemistry has prompted
the advances on the therapeutic potential of this system.
1,3,4-Thiadiazepine derivatives have been found to be potent drug in
pharmaceutical industries and exhibited various biological activities due to the presence
of  the -N=C-S group111. Thiadiazepines are not only known for their potent antimicrobial
activities112 but they are also excellent charge generating agent113. They also act as
intermediate for preparation of substituted caprolactams useful for the treatment of  HIV
disease114.
SYNTHETIC ASPECTS
Different methods for the synthesis of 1,3,4-thiadiazepine derivatives
documented in literature are as follows.
1. Hassan A. A et al.115 have prepared 7-amino-2-organylimino-2,3-dihydro -1,3,4-
thiadiazepine-5,6-dicarbonitrile by the reaction of thiosemicarbazide and
tetracyanoethene in ethyl acetate with admission of air.
N
N
S
1
2
3
4 5
6
7
(I)
R
NH NH
NH2
S
+
N
NN
N
S
N
H
N
NH2
NHR
N
N
Ethyl acetate
air
(II)
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2. Brukstus. A. et al.116 have synthesised 7-chloro-9-methyl-thiopyrimido[5,4-f][1,2,4]
triazolo[3,4-b][1,3,4] thiadiazepine by the reaction of 4,6-dichloro-2-methylthio
pyrimidine-5-carboxaldehyde with 3-substituted -4-amino -1,2,4-triazole-5-
thiones at 50-60 oC.
3. OM Prakash et al.117 have prepared thiadiazepine by Michael type addition
of 4-amino-3-mercapto-1,2,4-triazole to α , β,-unsaturated carbonyl compounds.
4. R. Gururaja et al.118 have synthesised quinoline thiadiazepine derivatives by
condensation of 2-chloro-6-substituted quinoline-3-carboxaldehyde with
thiocarbohydrazide in pyridine.
5. B. P. Nandeshwarappa et al.119 have prepared pyrazolo[3,4-e] [1,2,4] triazolo
[3,4-b][1,3,4] thiadiazepine by using microwave irradiation.
N
N
Cl
Cl
CHO
MeS
+
N
N
H
NH2
S
N
N
N
N
N
SMeS
(III)
N
N N
NH2
R SH
+
N
N N
R S
N
O
R'
R'
(IV)
R CHO
Cl
+ S
NH
NH2
NH
NH2
Pyridine
N
S
N
NH
R
NH2(V)
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THERAPEUTIC IMPORTANCE
From the literature survey it was revealed that 1,3,4-thiadiazepines are better
therapeutic agents. The important biological activity is shown as under.
1. Antibacterial120
2. Antiviral121
3. Antidepressant122
4. Antipsychotic123
5. Anti HIV124
6. Antiarrythmic125
7. Anticonvulsant126
8. CCK antagonists127
9. Gastrin receptor antagonists128
10. Antitumor129
Lebegue N et al.130 have synthesised novel thiadiazepine derivatives. These
molecules were evaluated for their antiproliferative activity toward the murine L1210
leukemia cell  line. The 4-methoxyphenylethyl group substituted on the pyridinyl nitrogen
of the benzo pyrido-thiadiazepines  are found to be essential for the antiproliferative
activity. B.Shivarama Holla and co-workers131 have prepared nitrophenyl furfurylidine
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazepine and screened for their antibacterial and antiviral
properties. Denis Pires de Lima132 have investigated thiadiazepines (VI) useful as
angiotensin converting enzyme (ACE) inhibitors and Jordi  Bolos et al.133 reported
them as an important  class of antihypertensive drug.
Elevated levels of tumor necrosis factor alpha(TNF-alpha) have been associated
with several inflammatory disease so,Cherney R J et al.134 have designed, synthesised
NH
S
N
N
O COOH
COOH
(VI)
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and evaluated of benzothiadiazepine hydroxamates as selective tumor necrosis factor-
alpha converting enzyme inhibitors. M.Kidwai et al.135 have reported thiadiazepines as
potential antimicrobial agent. R.Gururaja et al.136 have documented anthelmintic activ-
ity of 1,3,4-thiadiazepine (VII).
Ammar Y A. et al.137 have discovered  thiadiazepine derivatives  as
possible potential drug for fungal infection. Kalluraya B et al.138 have synthesised
thiadiazepines and screened for their antibacterial activities. Most of the synthesised
compounds showed significant activity against both Gram positive and Gram negative
bacterial strain. U. V. Laddi and co-workers139 have prepared triazolo-thiadiazepines
(VIII) and tested for their  antimicrobial and antituberculosis activities. Ashutosh Singh
and Nizamuddin140 have prepared thiadiazepines (IX) and reported their molluscicidal
activity.
Recently, Anshu Dandia et al.141 have discovered thiadiazepines (X) and screened
for their antifungal activity. Kamble R and Sudha B.142 have prepared novel 1,3,4-
thiadiazepines and reported them as cardiovascular agents.
N
S
N
NH N
R2
R1
(VII)
N
N N
N
S
Ar
R
C6H5
O CH2
N
N N
N
S
CH3
CH3
R
(VIII) (IX)
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Thus, significant biological properties associated with thiadiazepine
derivatives have aroused considerable interest to design the compounds in which
therapeutically active triazole nucleus is incorporated and to study their pharmacological
profile, which have been described as under.
SECTION-I :SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-(o,p-
DICHLOROPHENYL)-1,2,4-TRIAZOLO[3,4-b] SUBSTITUTED
QUINOLINO[2’,3’-f]-1”,3”,4”-THIADIAZEPINES
N
N
N
R
CH3
H
H
R
(X)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF  5-(o,p- DICHLOROPHENYL)-
1,2,4-TRIAZOLO[3,4-b]SUBSTITUTED QUINOLINO[2’,3’-f]-1”,3”,4”-
THIADIAZEPINES
During  the past years, considerable evidence has been accumulated to
demonstrate the efficiency of 1,3,4 thiadiazepines. To further assess the potential of
such a class of compounds, thiadiazepine derivatives of type (III) have been synthesised
by one pot reaction of  3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
with substituted  2-chloro-3-formyl-quinolines in the presence of K2CO3.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to have moderate activity as compared to known
antibiotics recorded on graphical chart No-3.
N
N N
N
N
S
Cl
Cl
R
Type (III)     R = Aryl
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N N
N
NH2
SH
Cl
Cl
Cl
O
NH NH2
Cl
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N
N N
N
N
S
Cl
Cl
NCl
OHC
R
R
DMF
K2CO3
REACTION SCHEME
        Type - (III)                   R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 5-(o,p-DICHLOROPHENYL)-1,2,4-TRIAZOLO [3,4-b]-
6-METHOXYQUINOLINO [3’,2’-f]-1”,3”,4”-THIADIAZEPINE
 Observed
Alkane C-H str. (asym.) 2925 2975-2950 430
-CH3 C-H str. (sym.) 2842 2880-2860 “
C-H i.p.def. (asym.) 1479 1470-1435 “
C-H o.o.p. def. (sym.) 1367 1390-1370 “
Aromatic C-H  str. 3116 3080-3030 431
C=C str. 1594 1585-1480 “
C-H i.p. def. 1120 1125-1090 “
C-H o.o.p. def 827  835-810 “
Triazole C=N str. 1612 1612-1593 430
moiety C-N str. 1305 1350-1200 434
N-N str. 1004 1050-1010 430
C-Cl str. 732 800-600 434
Thiadiazepine C-S-C str. 698  700-600 430
N-N str. 1004                   1050-1010                 “
(overlapped)
Ether C-O-C str. (asym.) 1269 1275-1200  431
C-O-C str. (sym.) 1066 1075-1020  “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N N
N
N
S
O CH3
ClCl
65Thiadiazepines....
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF  5-(o ,p-DICHLOROPHENYL)-1,2,4-TRIAZOLO
[3,4-b]-6-METHOXYQUINOLINO[3’,2’-f]-1”,3”,4”-THIADIAZEPINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.99 3H singlet Ar-OCH3          -
2. 7.31-7.32 1H doublet Ar-Hc     Jcb - 2.36
3. 7.40-7.44 1H double Ar-Hb          -
doublet
4. 7.51 1H singlet Thiadiazepine          -
   N=CHX
5. 7.54-7.55 1H doublet Quinoline-HC     JCB - 2.37
6. 7.57-7.59 1H double Quinoline-HB          -
doublet
7. 7.95-7.98 1H doublet Ar-Ha     Jab - 9.20
8. 8.05-8.08 1H doublet Quinoline-HA     JAB - 8.33
9. 9.47 1H singlet Quinoline-HD          -
N
N N
N
N
S
Cl
O
CH3
Cl
a
b
c
D
C
A
B
X
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EXPANDED AROMATIC REGION
N
N N
N
N
S
Cl
O
CH3
Cl
a
b
c
D
C
A
B
X
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF  5-(o,p- DICHLOROPHENYL)-
1,2,4-TRIAZOLO[3,4-b] SUBSTITUTED QUINOLINO[2’,3’-f]-1”,3”,4”-
THIADIAZEPINES
(A) Synthesis of Potassium o, p-dichlorobenzoyl dithiocarbamate
See [A]  part-I,  section-I  (C)
(B) Synthesis of 3-Mercapto-4,N-amino-5(-o,p-dichlorophenyl)-1,2,4-triazole
See [A]  part-I,  section-I  (D)
(C) Synthesis of Substituted 2-chloro-quinoline-3-carboxaldehydes143
These were prepared by the reaction of substituted acetanilide with DMF
and POCl3 using a well known Villsmeierhaack rearrangement.
(D) Synthesis of 5-(o,p-Dichlorophenyl) -1,2,4-triazolo[3,4-b] methoxy
quinolino [2’,3’-f]-1",3",4"-thiadiazepines
A mixture of 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01M) and 2-chloro-3-formyl-6-methoxy quinoline (2.20g, 0.01M) in dry
DMF (20 ml) and anhydrous K2CO3 (2.09 g) was refluxed at 80oC for 4 hrs. It was
cooled and poured onto crushed ice. The product was isolated and crystallised from
ethanol. Yield 62%, m.p. 155oC (C19H11Cl2N5OS ; required : C, 53.28; H, 2.59; N,
16.28, found : C, 53.40; H, 2.65; N,16.35%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
Similarly other substituted 1,3,4-thiadiazepines were synthesised. The
physical data are recorded in Table No. 3.
(E) Antimicrobial activity of 5-(o,p-Dichlorophenyl) -1,2,4-triazolo[3,4-b]
substituted  quinolino [2’,3’-f]-1",3",4"-thiadiazepines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 3.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that 1,3,4 thiadiazepine
derivatives of type (III) were found to be moderately active against Gram positive bacteria
B. coccus.and S. aureus, and also shown promising activity against Gram negative
bacteria like E.aerogenes and P.aeruginosa..
The maximum activity was observed in compound bearing R=8-methyl against
S. aureus. The significant activity was observed in compounds having R=6-methoxy,
6,8-dimethoxy and 6,7-dimethoxy substituents against B. coccus.
In case of  E.aerogenes all the  compounds were least active,while the compounds
bearing R=6-methoxy and 7-chloro displayed better activity. The compounds having
R=8-methoxy, 6-fluoro,7-chloro and 8-chloro have shown remarkable activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited mild activity against A. niger  except compounds
having R=6-fluoro, 7-chloro and 6,8-dimethyl showed highest activity against  A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz.greseofulvin.
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INTRODUCTION
 In six membered ring system, the presence of two nitrogen and one sulfur hetero
atom defines an interesting class of compounds, the thiadiazines. These may be of four
types : (I) 1,2,4-thiadiazine,  (II) 2H-1,2,6-thiadiazine, (III) 2H-1,3,4-thiadiazine (IV)
2H-1,3,5-thiadiazine. The 1,3,4-thiadiazine system was first reported by P. K. Bose144
in the year 1924.
1,3,4-Thiadiazine derivatives are studied extensively because it represents one
of the most active class of compounds possessing a wide spectrum of pharmacological
activities. 1,3,4-Thiadiazine derivatives are involved in many biological processes and
serves as an synthetic drugs, including various medicinally interesting compounds. 1,3,4-
Thiadiazines are useful for the synthesis of tri and tetracyclic heterocyclic compounds.
SYNTHETIC ASPECTS
Different methods for the synthesis cited in literature are as follows.
1. Ibrahim Yehia A.  and co-workers145 have synthesised  stereospecific synthesis
of 6,7-dihydro-5H -1,2,4-triazolo[3,4-b] [1,3,4] thiadiazine.
NH
S
N
1
2
3
4
5
6 NH
S
N
N
S
N
N
S
N
2H-1,2,4 - (I) 2H-1,2,6 - (II) 2H-1,3,4 - (III) 2H-1,3,5 - (IV)
N
N N
N
R SH
CH
Ar
+ R'-CO-CH2-Br
DMF / Et3N
NaBH4
N
N N
R
NH
S
H
H
Ar
R'
(V)
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2. Heravi  M. M. et al.146 have synthesised 1,3,4-thiadiazine by the cyclisation
of  4-amino-3-mercapto -6-methyl[1,2,4] triazine-5-one with phenacyl bromide.
3. M. Rahimizadeh et al.147 have prepared 1,3,4-thiadiazine by the reaction of
2,4-dichloro-6-methyl-5-nitropyrimidine with dithiazone.
4. Jean-Damien Charrier et al.148 carried out thionation of benzil hydrazones
with Lawesson’s reagent which afforded 1,3,4-thiadiazine derivatives by intramolecular
cyclisation.
5. A novel  and  facile strategy for the synthesis of  substituted 2-amino-1,3,4-
thiadiazine on solid support is described  by  John Paul Kilburn and co-workers149.
6. Wang X-C. et al.150 condensed 4-amino -3-2(benzo(b) furyl)-5-mercapto
triazole and α-bromo acetophenone under microwave irradiation to yield
triazolo thiadiazine.
N
N
N
NH2
SH O
CH3
+ Ph-CO-CH2-Br N
N
N
N
S O
CH3
Ph
(VI)
N
N
Cl Cl
CH3
NO2
+
N
N
Cl
CH3
S
N
N
R
Ph
NH NH
Ph
NH
NH PhS
(VII)
S
N
N
R1
R2
NH
O
OH
Pol O NH
F Moc
(VIII)
N
N N
NH2
SH
O
+ Ph-CO-CH2-Br M.W. N
N N
N
S
Ph
O
(IX)
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THERAPEUTIC IMPORTANCE
Thiadiazines and substituted thiadiazines are actively involved in pharmacologically
useful entities. Some compounds have proved to be successful chemotherapeutic agent
which are discribed as under.
1. Analgesic151
2. Antimicrobial152
3. Antiinflammatory153,154
4. Antidepressant155
5. Cardiovascular156,157
6. Antifungal158
D. Katiyar et al.159 have synthesised thiadiazines and screened for their in vitro
antitubercular activity  against Mycobacterium tuberculosis H37Rv. Three    compounds
showed antimycobacterial activity with MIC 12.5 µg/ml. Compounds were tested
in vitro against five multidrug resistant (MDR) strains of M.tuberculosis and were found
to be active. B. S. Holla et al.160 have documented thiadiazine derivatives (X) as
antimicrobial agent. Balladka Kunhanna Sarojini et al.161 discovered novel thiadiazines
and reported them as an anticancer agent. Among all the synthesised compound four
compounds were found to be active against NCI-H460 (lung), MCF7 (breast), SF268
(CNS) in the preliminary anticancer study.
Lee An Rong Taiwan 162 have patented triazolo thiadiazines (XI) as anti-inflammatory
agent. Dawood K. M. et al.163 have investigated new 1,3,4-thiadiazine derivatives and
evaluated them as antimicrobial agent. Kalluraya B. et al.164 have reported
3-substituted 7H-6-(6-bromo-3-coumarinyl)-5-triazolo [3,4-b][]1,3,4-thiadiazines (XII)
N
N
N N
S
Cl
F
Cl
R1
R2
N
N
S
N
N
R
EtOOC
(X) (XI)
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and subjected to antibacterial activity. Arranz Esther et al.165 have prepared thiadiazine
derivatives as nonnucleoside reverse transcriptor inhibitors, that  inhibit human
immunodefeciency virus type-1 replication. Renuka devi and Biradar166 have reported
triazolo thiadiazine derivatives (XIII) as anthelmintic, antiinflammatory and anticatatonic
activity.
Tuberculosis is one of the most devastating disease preliminarily, due to several
decades of neglets. The impetus for developing new structural classes of antituberculer
drug comes from the emergence of multi-drug-resistance (MDR) strain to commonly
use drugs. As a part of  these programme, Nayyar and Jain 167 have synthesised some
new thiadiazine derivatives which were used as antitubercular agent.
Khanum S. A et al.168 have synthesised triazolo thiadiazine analogues via
multistep synthesis and the compounds were tested against variety of fungal and
bacterial strains in comparison to Flucanazole and Chloramphanicol  respectively.
B. Shivarama Holla et al.169 discovered nitrophenyl furfurylidine-1,2,4-triazolo
thiadiazine and reported them as antiviral agent. Balkrishna et. al.170 synthesised
thiophene heterocycles of 6-(5-aryl-2-thienyl)-7H-s-triazolo [3,4-b]-1,3,4-thiadiazines
and reported that the chlorine  containing compounds were significantly active against
E. coli. (IVX).
N
H
N
NN
N
S
Ph
R
Ph(XIII)
O O
Br N
N
S
N
N
R
(XII)
N
N
N
N
S
S
NO2
R
(XIV)
R = H, alkyl, aryl, (aryloxy) methyl
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Shiradkar M. and Shiva Prasad 171 have documented the triazolo thiadiazine
and evaluated them as antibacterial, antifungal and antitubercular agent. Jonus Rochus
et. al.172 have prepared new thiadiazine derivatives useful as phosphodiesterase IV
inhibitors and cardiovascular agent (XV). Hansen J.B.et al.173 have prepared 1,3,4-
thiadiazine 1,1 dioxide derivatives, which are  shown to be a potent  kir 6.2 / SUR1
selective  (KATP) channels opener. ATP sensitive potassium (KATP) channels have
important function in  neuroendocrine tissues, in smooth and skeletal muscle and in the
heart. In pancreatic beta cells the (KATP) channels,which are formed by 4 ion channels
(Kir 6.2) and 4regulatory sulfonylurea   receptor  (SUR1) control the glucose stimulated
release of insulin.
 Spalinska K et al.174 have synthesised some novel thiadiazines and check for
their antibacterial activity. Karnik A. V. et al.175 have investigated chemoselectivity of
novel hetero cyclopenta[b] chrysene derivatives namely 6-aryl-2-2a-dihydro-
naptho[2’,1,5,6] pyrazo[4,3-e] [1,2,4] triazolo[3,4-b][1,3,4]thiadiazine and studied their
antimicrobial activity and molecules exhibited good to excellent activity as compared to
standard drug.
In view of the potential biological activities of 1,3,4-thiadiazine ring system, it
was of interest to preparing some novel derivatives of this family of heterocyclic ring
bearing triazole nucleus, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 5’-ARYL
  -5-(o,p-DICHLOROPHENYL)-[3,4-b]-1,2,4-TRIAZOLO[1’,3’,4’]-
 THIADIAZINES
S
N N
N
CH3
R
O
C
O
OCH3
OCH3
(XV)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5’-ARYL-5-(o ,p -
DICHLOROPHENY)-[3,4-b]-1,2,4-TRIAZOLO-[1’,3’,4’]- THIADIAZINES
1,3,4-Thiadiazine derivatives occupy a unique place in the field of medicinal
chemistry due to wide range of biological activities exhibited by them. In view of these
facts, it was contemplated to synthesise thiadiazine derivatives of type (IV) by
condesation of 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole with different
substituted phenacyl bromides.
The structures of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to have moderate activity as compared to known
antibiotics recorded on graphical chart No-4.
N N
N
N
S
Cl
R
Cl
Type (IV)         R = Aryl
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N N
N
NH2
SH
Cl
Cl
Cl
O
NH NH2
Cl
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
RCOCH2Br
N N
N
N
S
Cl
R
Cl
REACTION SCHEME
        Type - (IV)                   R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 5’-(METHYLPHENYL)-5-(o,p-DICHLOROPHENYL)-
[3,4-b]-1,2,4-TRIAZOLO -1’,3’,4’-THIADIAZINE
 Observed
Alkane C-H str. (asym.) 2918 2975-2950 430
-CH3 C-H str. (sym.) 2852 2880-2860 “
C-H i.p.def. (asym.) 1440 1470-1435 “
C-H o.o.p. def. (sym.) 1350 1390-1370 “
Aromatic C-H  str. 3064 3080-3030 431
C=C str. 1542 1585-1480 “
C-H i.p. def. 1116 1125-1090 “
C-H o.o.p. def 839     835-810 “
Triazole C=N str. 1595 1612-1593 430
moiety C-N str. 1163 1220-1020 434
N-N str. 1072 1250-1010 430
C-Cl str 759 800-600 “
Thiadiazine N-N str. 1072 1250-1010 “
                                             (overlapped)
C-N str. 1163 1220-1020 431
                                             (overlapped)
C-S str. 690 700-600 434
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 426.2
 464.8
 503.4
 540.0
 613.3
 644.2
 690.5
 731.0
 759.9
 815.8
 839.0
 869.8
 898.8
 956.6
1006.8
1072.3
1116.7
1163.0
1228.6
1294.1
1350.1
1406.0
1440.7
1500.5
1542.9
1595.0
2852.5
2918.1
3064.7
3309.6
N N
N
N
S
CH3
ClCl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 5’-PHENYL-5-( o, p- DICHLOROPHENYL)-[3,4-b]-
1,2,4-TRIAZOLO -1’,3’,4’-THIADIAZINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 4.27 2H singlet -CH2         -
2. 7.45-7.56 4H doublet        Ar-Hee’,Ar-Hff’         -
3. 7.59-7.65 1H multiplet Ar-Hb                   -
4. 7.86-7.88 1H doublet Ar-Ha   J
ab
-6.72
5. 7.96-7.97 1H doublet Ar-Hc   J
cb
-1.89
6. 8.06-8.09 1H singlet Ar-Hg         -
N N
N
N
S
Cl
Cl
a
b
c
d
e
f
g
e'
f'
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EXPANDED AROMATIC REGION
N N
N
N
S
Cl
Cl
g
N N
N
N
S
Cl
Cl
a
b
c
d
e
f
g
e'
f'
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5’-ARYL- 5-(o,p-
DICHLOROPHENYL)-[3,4-b]-1,2,4-TRIAZOLO[1’,3’,4’]-THIADIAZINES
(A) Synthesis of Potassium o,p-dichlorobenzoyl dithiocarbamate
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of  5’-p-Methoxyphenyl -5-(o,p-dichlorophenyl)-  [3,4-b]- 1,2,4-
triazolo  [1’,3’,4’]-thiadiazines
A mixture of 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01 M), p-methoxyphenacyl bromide (2.28 g, 0.01 M) in dry methanol (50 ml)
was heated under reflux  for 5 hrs, then cooled and neutralised with aqueous pottasium
carbonate solution. The solid thus separated out was filtered, washed with water and
crystllised from ethanol. Yield 62%, m.p. 182oC (C17H12Cl2N4OS; Required :
C, 52.18; H, 3.09; N, 14.32;  Found : C, 52.40; H,3.20; N, 14.44%).
TLC solvent system : Ethyl acetate  : Hexane (3 : 7).
Similarly other phenacyl bromides have been condensed. The physical data are
recorded in Table No. 4.
(D) Antimicrobial activity of 5’-Aryl -5-(o,p-dichlorophenyl)-[3,4-b]- 1,2,4-
triazolo  [1’,3’,4’]-thiadiazines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 4.
84Thiadiazines....
   
 S
r.
   
 R
  M
ol
ec
ul
ar
   
M
ol
ec
ul
ar
   
   
M
. P
.
   
   
  R
f*
   
 Y
ie
ld
   
  %
 o
f N
it
ro
ge
n
   
 N
o.
   F
or
m
ul
a
   
  W
ei
gh
t
   
   
  o
C
   
   
V
al
ue
   
   
%
   
   
   
   
C
al
cd
.  
   
   
Fo
un
d
1
   
 2
   
   
 3
   
   
   
4
   
   
   
5
   
   
   
6
   
   
   
   
   
  7
   
   
   
   
   
 8
   
   
 9
TA
B
L
E
-4
 :
PH
Y
SI
C
A
L 
C
O
N
ST
A
N
T
S 
O
F 
 5
’-
A
R
Y
L
-5
-(
o,
p-
D
IC
H
L
O
R
O
PH
E
N
Y
)-
[3
,4
-b
]-
1,
2,
4-
T
R
IA
Z
O
L
O
-[
1’
,3
’,4
’]
-
   
   
   
   
   
   
   
T
H
IA
D
IA
Z
IN
E
S
*T
LC
 S
ol
ve
nt
 S
ys
te
m
 : 
Et
hy
l a
ce
ta
te
 : 
H
ex
an
e 
(3
 : 
7)
4a
4-
C
H
3-
C
6H
4-
C
17
H
14
C
l 2
N
4S
   
37
5.
25
 1
40
0.
50
55
   
14
.9
3
   
  1
5.
02
4b
4-
C
l-
C
6H
4-
C
16
H
9C
l 3
N
4S
   
39
5.
62
 2
14
0.
72
60
   
14
.1
6
   
  1
4.
32
4c
4-
F-
C
6H
4-
C
16
H
9C
l 2
FN
4S
   
37
9.
23
 1
55
0.
54
68
   
14
.7
7
   
  1
4.
85
4d
C
6H
5-
C
16
H
10
C
l 2
N
4S
   
36
1.
24
 1
90
0.
76
56
   
15
.5
1
   
  1
5.
59
4e
4-
O
C
H
3-
C
6H
4-
C
17
H
12
C
l 2
N
4O
S
   
39
1.
27
 1
82
0.
47
62
   
14
.3
2
   
  1
4.
44
4f
2,
4-
(C
l)
2-
C
6H
3-
C
16
H
8C
l 4
N
4S
   
43
0.
13
 1
70
0.
62
50
   
13
.0
3
   
  1
3.
13
4g
2,
4-
(F
) 2
-C
6H
3-
C
16
H
8C
l 2
F 2
N
4S
   
39
7.
20
 1
78
0.
74
68
   
14
.1
0
   
  1
4.
21
4h
3-
C
l,4
-F
-C
6H
3-
C
16
H
8C
l 3
FN
4S
   
41
3.
68
 1
42
0.
51
58
   
13
.5
4
   
  1
3.
68
4i
4-
B
r-
C
6H
4-
C
16
H
9B
rC
l 2
N
4S
   
44
0.
14
 1
58
0.
68
72
   
12
.7
3
   
  1
2.
82
4j
4-
N
H
2-
C
6H
4-
C
16
H
11
C
l 2
N
5S
   
37
6.
26
 1
80
0.
52
61
   
18
.6
1
   
  1
8.
71
4k
4-
O
H
-C
6H
4-
C
16
H
10
C
l 2
N
4O
S
   
37
7.
24
 1
38
0.
65
66
   
14
.8
5
   
  1
4.
94
85Thiadiazines....
051015202530
ZONE OF INHIBITION IN mm B.
 c
oc
cu
s
15
18
19
20
21
19
17
16
19
20
19
25
18
20
22
0
S.
 a
ur
eu
s
15
19
12
18
19
21
18
17
23
13
18
25
19
15
21
0
E.
ae
ro
ge
ne
s
19
16
19
21
22
18
14
15
17
16
19
20
21
22
19
0
P.
ae
ru
gi
no
sa
22
13
14
17
23
19
16
17
19
21
20
22
21
16
23
0
A
. n
ig
er
13
18
16
17
12
23
21
15
16
18
13
0
0
0
0
26
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
4k
A
m
ox
ic
ill
in
Be
nz
o
yl
pe
ni
ci
lli
n
C
ip
ro
f
lo
xa
ci
n
Er
yt
hr
om
yc
i
n
G
re
se
of
ul
vi
n
G
R
A
PH
IC
A
L 
C
H
A
R
T
 N
O
. 4
 : 
 A
N
T
IM
IC
R
O
B
IA
L
 A
C
T
IV
IT
Y
 O
F5
’-
A
R
Y
L
- 5
--
(o
,p
- D
IC
H
L
O
R
O
PH
E
N
Y
L
)
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
-[
3,
4-
b
]-
1,
2,
4-
T
R
IA
Z
O
L
O
[1
’,3
’,4
’]
-T
H
IA
D
IA
Z
IN
E
S
86Thiadiazines....
CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all the thiadiazine derivatives
of type-(IV) markedly  inhibit the growth of Gram positive & Gram negative bacterial
strains.
However, comparatively significant activity was observed in compounds with
R=4-methoxyphenyl and 4-aminophenyl against B.coccus. Compounds bearing
R=2,4-dichlorophenyl and 4-bromophenyl have fairly inhibit the growth of S.aureus
and zone of inhibition displayed by these compounds is (21mm) and (23mm).
In case of Gram negative bacterial strain,compounds  bearing R=phenyl and
4-methoxyphenyl  show significant activity against E.aerogenes. Almost all  compounds
were found mildly active against P.aeruginosa while the compounds bearing
R= 4-methylphenyl (22mm), 4-methoxyphenyl (23mm) and 4-aminophenylphenyl (21mm)
are highly active.
ANTIFUNGAL ACTIVITY
 All the compounds were active against A. niger. Maximum activity was shown
by the compounds bearing R=2,4-dichlorophenyl and 2,4-difluorophenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz.greseofulvin.
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INTRODUCTION
Five-membered nitrogen and sulphur containing heterocycles are traditional
objects of basic research. Furthermore, great attention is currently paid to the biologically
active compounds belonging to thiazolidine series. 4-Thiazolidinones possess thiazolidine
ring and carbonyl  group at 4-position. The cyclic structure was assigned after the
recognition of mercapto acetic acid as the primary product of hydrolysis of 3-phenyl-2-
phenylamino-4-thiazolidinone.
A well known antibiotic, actithiazic acid, isolated from a species of
streptomyces shows specific in vitro activity against M.tuberculosis, but it is inactive
in vivo probably due to antagonisation by biotin, bears the 4-thiazolidinone skeleton176.
The   chemistry of 4-thiazolidinone was reviewed in depth by F.Brown177 in 1962 and
by Newkom and A.Nayak178 in 1977.
SYNTHETIC ASPECTS
Several methods have been documented in literature. Some of them are as under.
1. R. A. Mane and coworkers179 have synthesised 4-thiazolidinones bearing
2-mercapto-4-methylimidazoles nucleus in presence of chloracetic acid
and sodiumacetate.
2. Tumul Srivastava et al.180 have synthesised thiazolidin-4-one by one pot synthesis.
4-Thiazolidinones have been assembled by  DCC mediated three component
reaction of amine, aldehyde and mercaptoacetic acid. The final compound is
obtained in quantitative yields within one hour.
NH S
O
        (I)
(II)
ClCH2COOH, NaOAC
ACOHN N
SH
CH3 NH
NH
NH
CH3
S
R
Ph
N N
SH
CH3 N
NCH3
R
N
S
O
Ph
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3. Jerome Blanchet et al181. have synthesised 2-imino-4-thiazolidinones from
readily accessible alkyl trichloromethyl carbinols and thiourea under mild
conditions.
4. Abdel Megid M and co-workers182 have prepared dimer type  4-thiazolidinone
derivatives.
5. C.V.Kavitha  and coworkers183 have prepared 4-thiazolidinone derivatives
by using microwave irradiation.
MECHANISM
Mercaptoacetic acid attacks on C=N group, adding  HSCH2COOH to the
carbon atom followed by the cyclisation.
R NH2 +
O
R1H
+
O
OH
SH + DCC
1 hrs
THF S
N
R1R
O
(III)
O
R1H
OH
CCl3RCl3CCO2H
Cl3CCO2Na
DMF,  20 C
Thiourea
NaOH
DME,   20 C
S NH
NH
R O
(IV)
NH2
OHMeO + R CHO
SH COOH
DCC, THF
M.W.
N
MeO
S
OH
R
O
(V)
N CH RR1
+
SH
O
OH
O
OH
CH3
R1
NHR
O CH3
R1
NR
(VI)
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Evidences have been accumulated for the nucleophilic attack of thioglycolic anion
on carbon of azomethine having positive character and nitrogen having negative
character. Simultaneous removal of water determines the rate and helps in cyclisation.
THERAPEUTIC IMPORTANCE
4-Thiazolidinone derivatives substituted at 2-and 3-positions are associated with
diverse biological activities.
Following types of activities have been reported.
1. Thrombin Inhibitors184
2. Antimicrobial185,186
3. Antipsychotic187
4. Antihypertensive188
5. Antidiabetic189
6. Bactericidal190,191
7. Antifungal192
8. CNS depressant193
9. Anti-inflammatory194
10. Anthelmintic195
11. Anticonvulsant196
12. Plant Growth Inhibitor197
13. H1-Histamine antagonists198
Maria Letizia Berreca et al.199 have documented a series of 2,3-diaryl-1,3-
thiazolidin-4-ones (VII). Some derivatives proved to be highly effective in inhibiting
HIV-1 replication at nanomolar concentration. SAR studies evidenced that the nature of
the substituents at the 2 and 3 positions of the thiazolidinone nucleus largly influenced
the in vitro antiHIV activity of this new class of potent antiviral agents. Bhawna Goel
et al.200 reported some new thiazolidinones and studied their anti-inflammatory,
ulcerogenic and cardiovascular activity. Orlinskii M.M.201 have synthesised some new
4-thiazolidinones (VIII) as antioxidant and antischistosomal agent.
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The synthesis and pharmacological activity of  5-arylidine-2-imino-4-
thiazolidinones (IX) are described by Rosaria Ottana202. All derivatives exhibited
significant activity levels in models of acute inflammation such as carrageenan-induced
paw and pleurisy edema in rats. The most interesting compound in such an experiment
was docked in the known active site of COX-2 protein and showed that its
4-methoxyarylidine  moiety can easily occupy the COX-2 secondary pocket considered
as the critical interaction for COX-2 selectivity.  Kerim Babaoglu et al.203 have synthesised
thiazolidin-4-one derivatives (X) . Most of  the compounds showed modest activity against
whole cell of  M.Tuberculosis. A. Rao et al.204 have prepared several 1,3-thiazolidin-
4-ones bearing a 2,6-dihalophenyl group at-C-2 and a substituted pyrimidin-2-yl ring at
the N-3 and evaluated them as anti-HIV agents. The results of the in vitro tests showed
that some of them were highly effective inhibitor of  human immunodeficiency virus type-1
(HIV-1) replication at 10-40nM concentration with minimal cytotoxycity. M.G. Vigorita
et al.205 have discovered a novel thiazolidinone derivatives, which was isolated as recemic
mixtures. After resolution the dextrorotatory compound is highly selective COX-2
inhibitor and the levorotatory one is moderately selective.
S
N
Ar
O
R
R1 S
N
(CH2)n
N
S
O O
SH SH
(VIII)(VII)
S N
N
O
CH3
R
R1
S
R3
R2
O
R1
O
OH
(X)(IX)
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CONTRIBUTION FROM OUR LABORATORY
Parikh et al. have synthesised variety of 4-thiazolidinone derivatives bearing
diphenyl sulphone206, substituted aryl207, arsanilic acid208 , 2-aryl 1,3,4,-
thiadiazole209, 2-benzyl-1,3,4-thiadiazole210, γ-picolinylamino211, s-triazine212 and
benzoylamino acetamido213 moieties of 4-thiazolidinone ring system (XI) and have been
reported as potent antimicrobial agents. H.H.Parekh and co-workers have synthesised
4-thiazolidinones bearing dapsone214, s-triazine215, acridine-9-yl216 and
thymoloxyacetamido217. 4-Thiazolidinone ring system (XI), which is represented as
under. General structures for above refereces is as under.
S
NX CH3
Z
O
Y
N C NH
O
N
N
H
N
NH Aryl
NH Aryl
N
NH
OCH2CONH-
S
NNS
O
O
NH C
O
OCH3
OCH3
OCH3
C-HN
O COOH
-HN-O2S
S
NN
CH2O
Cl
Cl
S
N CH3
CH3
CH3
CH2
Y = H, CH3CH2COOH ; Z = H, CH3, C6H5 ; R=Aryl
x =
; ;
; ;
;
;
(XI)
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Recently, Guniz Kucukguzel and co-workers218 have synthesised a series of
4-thiazolodinones (XII) and all synthesised compounds were screened for their
antimycobacterial activity against Mycobacterium Tuberculosis H37Rv.  Antiproliferative
and COX-2 inhibitor activity of some novel thiazolidinone derivatives are studied by
Rosaria Ottana et al.219 Synthesised compounds showed antiproliferative properties
on all tested cell lines. Paola Vicini, Athina Geronikaki and co-workers220 have
prepared new 4-thiazolidinone (XIII) and assayed in vitro for their antimicrobial
activity against Gram positive and Gram negative bacteria. The compound was very
potent   towards all the tested Gram positive microorganism.
In accordance with these observations, we have designed and explored  potential
molecules in which triazole nucleus is incorporated with a view to get better drug
potential. This lead to synthesis of some novel 4-thiazolidinones, which have been    ribed
as under.
SECTION-I :SYNTHESIS AND BIOLOGICAL EVALUATION OF  4,N-SUB-
STITUTED BENZALIMINO-3-MERCAPTO-5-(o,p-DICHLORO-
PHENYL)-1,2,4-TRIAZOLES
SECTION-II :SYNTHESIS AND BIOLOGICAL EVALUATION OF  2-ARYL-
  3-[5’-(o,p-DICHLOROPHENYL)-3-MERCAPTO-1’,2’,4’-
  TRIAZOL-4’-YL]-5H-4-THIAZOLIDINONES
F
F
OH
NH
N
S
N
O
CH3
O
NH
SNS
N
O
R
(XIII)(XII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
BENZALIMINO-3-MERCAPTO-5- (o , p-DICHLOROPHENYL)-1 ,2 ,4 -
TRIAZOLES
Much interest is focused around azomethine derivatives because of their wide
range of pharmacological properties. Hence, it was considered worthwhile to synthesise
azomethine derivatives of type (V) for better drug potential. The azomethine derivatives
were synthesised by the condensation of  3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-
1,2,4-triazole with different aromatic aldehydes in the presence of  sulphuric acid.
The structures of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to possess moderate activity as compared to known
antibiotics recorded on graphical chart No-5.
Type (V)             R = Aryl
N N
N
N
Cl
R
Cl
SH
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N N
N
NH2
SH
Cl
Cl
Cl
O
NH NH2
Cl
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
R-CHO
N N
N
N
Cl
R
Cl
SH
Con. H2SO4
REACTION SCHEME
        Type - (V)                   R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF  4,N-p-METHOXYBENZALIMINO-3-MERCAPTO-5-
(o,p- DICHLOROPHENYL)-1,2,4-T R I A Z O L E
 Observed
Alkane C-H str. (asym.) 2920 2975-2950 430
-CH3 C-H str. (sym.) 2837 2880-2860  “
C-H i.p.def. (asym.) 1463 1470-1435  “
C-H o.o.p. def. (sym.) 1355 1390-1370  “
Aromatic C-H  str. 3029 3080-3030 431
C=C str. 1569 1585-1480  “
C-H i.p. def. 1097 1125-1090  “
C-H o.o.p. def   831  835-810  “
Triazole C=N str. 1604 1612-1593 430
moiety C-N str. 1166 1220-1020 “
N-N str. 1029 1050-100 434
C-Cl str.  779  600-800  “
C-S str. 646                      700-600 432
Ether C-O-C str. (asym.) 1255 1275-1200 430
C-O-C str. (sym.) 1029 1075-1020  “
                                              (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
N
N
O
CH3Cl
Cl
SH
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 405.0
 422.4
 480.2
 528.5
 812.0
 831.3
1029.9
1097.4
1166.9
1255.6
1303.8
1355.9
1423.4
1463.9
1512.1
1569.9
1604.7
2339.5
2360.7
2837.1
2920.0
3120.6
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 4,N-p-METHOXYBENZALIMINO- 3-MERCAPTO-5-
(o,p- DICHLOROPHENYL)-1,2,4-T R I A Z O L E
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 2.38 3H singlet Ar-CH3          -
2. 7.20-7.23 2H doublet Ar-Hdd’ Jde-8.04
3. 7.58-7.61 2H doublet Ar-Hee’ Jed-8.11
4. 7.37-7.39 1H doublet Ar-Hb          -
5. 7.39-7.40 1H doublet Ar-Ha          -
6. 7.47 1H singlet -CHf          -
7. 7.50-7.51 1H doublet Ar-Hc Jcb-2.26
8. 13.8 1H singlet -SHg          -
a
c
d
N N
N
N
Cl
CH3
Cl
SH
b
e
d' e'
f
g
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EXPANDED AROMATIC REGION
N N
N
N
Cl
CH3
Cl
SH
a
c
d
N N
N
N
Cl
CH3
Cl
SH
b
e
d' e'
f
g
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
BENZALIMINO-3-MERCAPTO-5- (o ,p-DICHLOROPHENYL)-1 ,2 ,4 -
TRIAZOLES
(A) Synthesis of Potassium o,p-dichlorobenzoyl dithiocarbamate
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of 4,N-p-Methoxybenzalimino-3-mercapto-5-(o,p-dichlorophenyl)-
1,2,4-triazoles
A mixture of 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01 M) and  p-methoxybenzaldehyde (1.36 g, 0.01 M) in absolute alcohol (25
ml) in presence of sulphuric acid as a catalyst were refluxed for 8 hrs, then cooled and
poured on to crushed ice. The solid thus separated out was filtered, washed with water
and crystllised from ethanol. Yield 74%, m.p. 114oC (C16H12Cl2N4OS; Required :
C, 50.67; H, 3.19; N, 14.77;  Found : C, 50.80; H,3.29; N, 14.85%).
TLC solvent system : Ethyl acetate  : Hexane (4 : 6).
Similarly other derivatives have been synthesised. The physical data are recorded
in Table No. 5.
(D) Antimicrobial activity of 4,N-substituted benzalimino-3-mercapto-5-
(o,p-dichlorophenyl)-1,2,4-triazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 5.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded that all the azomethine
derivatives of type-(V) have displayed considerable activity against  Gram positive &
Gram negative bacterial strains.
In case of Gram positive bacterial strain maximum activity was observed in
compounds bearing R = 3-nitrophenyl, 2-chlorophenyl and 3,4-dimethoxyphenyl against
B.coccus. The significant activity was displayed by compounds having R=3-nitrophenyl
and  2-methoxy phenyl  against S.aureus.
In case of Gram negative bacterial strain ,compounds  bearing R=3-hydroxyhenyl,
4-hydroxypheny and 2-methoxyphenyl showed good activity against E.aerogenes.
Almost all  compounds were found mild active against P.aeruginosa, maximum activity
observed in R= 4-hydroxyphenyl (20mm) and 2-chlorophenyl (22 mm).
ANTIFUNGAL ACTIVITY
It has been found that all the compounds were active against A. niger.Maximum
activity was shown by the compounds bearing R=2-nitrophenyl and 4-fluorophenyl
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-3-[5’-(o ,p-
DICHLOROPHENYL)-3-MERCAPTO-1’,2’,4’-TRIAZOL-4’-YL]-5H-4-
THIAZOLIDINONES
Thiazolidinone derivatives represent one of the most active class of compounds
having a wide spectrum of  biological activities. With an aim to getting better therapeutic
agent, the preparation of 4-thiazolidinone derivatives of type (VI) by condensation of
azomethines of type (V) with thioglycolic acid in presence of anhydrous ZnCl2 has been
undertaken.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to have moderate activity as compared to known
antibiotics recorded on graphical chart No-6.
Type (VI)         R = Aryl
N N
N
Cl
Cl
SH
N
S
O R
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REACTION SCHEME
        Type - (VI)                   R=Aryl
N N
N
NH2
SH
Cl
Cl
R-CHO
N N
N
N
Cl
R
Cl
SH
Con. H2SO4
SH-CH2-COOH
Anhy. ZnCl2
110-120    ,  10-12 hrs
N N
N
Cl
Cl
SH
N
S
O R
C
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 2-(p-METHYLPHENYL)-3-[5’-(o,p- DICHLOROPHENYL)
-3-MERCAPTO-1’,2’,4’-TRIAZOL-4’-YL]-5H-4-THIAZOLIDINONE
 Observed
Alkane C-H str. (asym.) 2974 2975-2950 430
-CH3 C-H str. (sym.) 2860 2880-2860    “
C-H i.p.def. (asym.) 1494 1470-1435    “
C-H o.o.p. def. (sym.) 1369 1390-1370    “
Alkane -CH2-C=O str. 1438 1420-1410 432
-CH2
Aromatic C-H  str. 3066 3080-3030 431
C=C str. 1562 1585-1480    “
C-H i.p. def. 1112 1125-1090    “
C-H o.o.p. def  815  835-810    “
Triazole C=N str. 1629 1640-1605 434
moiety C-N str 1170 1220-1000 430
N-N str. 1043 1050-1010    “
C-Cl str.  790 600-800    “
Thiazolidinone -C=O str. 1712 1760-1655 433
C-N str. 1170 1220-1000 430
                                                 (overlapped)
C-S-C str. 675  720-570   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N N
N
N
Cl
S
O
CH3
Cl
SH
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 2-(p-CHLOROPHENYL)-3-[5’-(o,p- DICHLORO-
PHENYL) -3-MERCAPTO-1’,2’,4’-TRIAZOL-4’-YL]-5H-4-THIAZOLIDINONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 4.33 2H singlet -CH2(f)         -
2. 7.48-7.50 3H           multiplet      Ar-Ha,Ar-Hb,         -
    Ar-Hc
3. 7.64-7.67 2H doublet Ar-Hdd’               Jde- 9.42
4. 7.88-7.90 2H doublet Ar-Hee’     Jed - 8.72
5. 8.01 1H singlet -CHg         -
N N
N
Cl
Cl
SH
N
S
O
Cl
a
b
c
d
d'
e
e'
f
g
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EXPANDED AROMATIC REGION
N N
N
Cl
Cl
SH
N
S
O
Cl
a
b
c
d
d'
e
e'
f
g
H3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-3-[5’-
(o ,p-DICHLOROPHENYL)-3-MERCAPTO-1’,2’,4’-TRIAZOL-4’-YL]-5H-4-
THIAZOLIDINONES
(A) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(B) Synthesis of 4,N-Substituted benzalimino-3-mercapto-5(o,p-dichlorophenyl)-
1,2,4-triazoles
See [A] Part-IV, Section-I (C)
(C) Synthesis of  4-Methoxyphenyl-3-[5’-( o,p-dichlorophenyl)- 3-mercapto-1’,2’,4’-
triazol-4’-yl] -5H-4-thiazolidinone
A mixture of 4,N-p-methoxybenzalimino-3-mercapto-5-(o,p-dichlorophenyl)-
1,2,4-triazoles (3.79g, 0.01 M) and thioglycolic acid (1.22 ml, 0.01M) was refluxed
continuously at 110-120oC for 12 hrs. Then the resulting mixture was poured on to
crushed ice and neutralized with sodium bicarbonate solution.The product was isolated
and crystllised from  DMF. Yield 64%, m.p. 195oC (C18H14Cl2N4O2S2; Required :
C, 47.69; H, 3.11; N, 12.36;  Found : C, 47.81; H, 3.23; N, 12.50%).
TLC solvent system : Ethyl acetate  : Hexane (2 : 3).
Similarly other derivatives have been synthesised. The physical data are recorded
in Table No. 6.
(D) Antimicrobial activity of  2-Aryl-3-[5’-( o,p-dichlorophenyl)- 3-mercapto-1’,2’,4’-
triazol-4’-yl] -5H-4-thiazolidinones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 6.
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051015202530
ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of  4-thiazolidinones of the type-(VI) revealed that all
the compounds were able to inhibit the growth of Gram positive & Gram negative bacterial
strains.
In case of Gram positive bacterial strain maximum activity was observed in
compounds bearing R = 4-methoxyphenyl, 4-hydroxyphenyl, 3-nitrophenyl and
4-chlorophenyl against B. coccus. The significant activity was displayed by compounds
having R= 4-fluorophenyl and 2-hydroxyphenyl  against S. aureus.
In case of Gram negative bacterial strain ,the significant activity was displayed
by the compounds bearing R= 4-methylphenyl, 4-fluorophenyl and 2-methoxyphenyl
which fairly inhibit the growth of E.aerogenes. Almost all  compounds were found to be
mildly active against P.aeruginosa, while R=4-chlorophenyl, 2-methoxyphenyl and
3-nitrophenyl which showed the zone of inhibition respectively (22mm), (20mm) and
(23mm).
ANTIFUNGAL ACTIVITY
 Almost all the compounds displayed mild activity except compounds bearing
R= 4-methoxyphenyl, 3,4-dimethoxyphenyl and 2-methoxyphenyl against A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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INTRODUCTION
The first “Mannich reaction” took place in 1912 by Carl Mannich.Today, much
interest has been focused on the synthesis of Mannich bases due to its wide variety of
biological  activities. Mostly, they are found to be antineoplastic, analgesic and antibiotic
agents. Several therapeutically important molecules prepared through Mannich reaction
have received more attention in last few years221. Mannich bases are also employed as
intermediate in industrial chemical synthesis222,223 and also have gained importantance
in polymer224 chemistry.
SYNTHETIC ASPECTS
Different methods have been cited in literature to synthesise Mannich bases which
have been described as under.
1. Robin A. Fairhurst et al.225 have synthesised Mannich base by 3-methyl-
1,3-oxazolidine and 3,4-dimethyl-5-phenyl oxazolidine reacts with acidic reagents
under aprotic condition to afford reactive intermediates that interact with
nucleophilic aromatic substractes and enolsilyl ethers to afford good yields of
Mannich base.
2. B.Shivarama Holla et al.226 have prepared Mannich base derivative by amino
methylation of 3-substituted 4-[5-(4-methoxy-2-nitrophenyl)-2-furylidenes]
amino-5-mercapto-1,2,4-triazole with formaldehyde and various secondary
amines.
OCH3
+ N O
CH3
t -BOMSi
OCH3
N OSi T Bu Me2
CH3
OCH3
N OH
CH3
Me2 NO2P/CCl4
Zn/MeI/ACOH
OCH3
NH
CH3
(I)
114Mannich Bases....
3. Ulrich Girreser et al.227 have synthesised Mannich base by the reaction of
7 - a r y l - 5 , 6 - d i h y d r o  p y r i d o [ 2 , 3 - d ] p y r i m i d i n e ( 1 H , 3 H ) - 2 , 4 - d i o n e s ,
phosphorousoxychloride and N,N-dimethyl formaldehyde.
4. Fox , Raymond C. et al.228 have reported the preparation of some novel metal
selective Mannich base.
5. Suman Sahoo et al.229 devoloped an efficient process for a simple and fast
reaction of different aldehydes , ketones amines to afford corresponding Mannich
base using catalytic amount of ionic liquid.
MECHANISM
The Mannich reaction is an example of nucleophilic addition of an amine to a
carbonyl group followed by elimination of a hydroxyl anion to the Mannich base. The
Mannich base is an electrophile, which reacts in step two in a second nucleophilic
N
N
N
O
CH3
O
CH3
Ar
DMF/POCl3
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O CH3
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addition with a carbanion generated from  a compound containing an acidic proton. The
Mannich reaction is also considered as condensation reaction. The mechanism is
described as under.
THERAPEUTIC IMPORTANCE
A wide variety of biological activities and industrial applications have been
encountered with several Mannich bases such as.
1. Antibacterial230
2. Antipsychotic231
3. Cytotoxic activity232
4. Antiinflammatory233
5. Antitumor234
6. Antileishmanial235
7. Antifungal236
8. Antileukemic237
9. Antiherpes238
10. Anticonvulsant239
11. Antimicrobial240
Haitao Chen et al.241 have documented alkylidine cyclopentanone Mannich bases
(V) which possess anticancer activity. Most of the substances were found to be active
towards various human cancer cell line. Maria Grazia Ferlin et al.242 have discovered
novel Mannich bases obtained by aminoalkylation of 3H-pyrrolo[3,2-f]quinoline and
reported them as potential vasorelaxing agents.
R
NH
R1
. . + CO
H
H
R1
N C
H
HR
R1
N C
H
H
OH
R1
N+ CH2
R RH
+
OH
_
R1
N C
H
HR
+
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Nable A. et al. 243 have synthesised Mannich bases (VI) and excellent fungicidal
result were obtained against the various types of fungi under investigation. Sheela Joshi
et al.244 have prepared Mannich base of isoniazide which showed better antitubercular
activity than isoniazide. Halis Suleyman et al.245 discovered 3-benzoyl-methyl-4-phenyl-
4-piperidinol hydrochloride and tested them as antiinflammatory agent which showed
their effect on acute and chronic phase of inflamation, respectively. Seshaiah  Shridhar
et al.246 have discovered Mannich base derivatives and screened for their anticonvulsant
activity. Francisca Lopes et al.247 have prepared a novel Mannich bases which displayed
antimalarial activity against the multi drug resistance plasmodium falciparum strain Dd2
and demonstrated no significant loss in activity compared to Amodiaquine.
Idan Chiyanzu et al.248 have documented Mannich base derivatives (VII) and
studied their in vitro antiplasmodial activity and inhibition of falcipain-2. These
compounds showed better potential against sensitive strain of P.falciparum. Jingli Wang
et al.249 have investigated new derivatives of Mannich bases (VIII) and evaluated them
as anticancer agent. Dharmarajan Shriram et al.250 have synthesised Mannich base of
isoniazide and screened for antimycobacterial activity and the synthesised compounds
were found to be most active than isoniazide.
CH3
R2
R1
Am
HCl
Am=(CH3)2N , O NH O NH, ,
NH
(V)
(VII)
N
NH
N
X
O
R1
R2
Cl
N
CH2COOR
N
O
(VI)
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Surendra N. Pandeya and co-workers 251 have synthesised Mannich bases of
norfloxacin. Investigation of in vitro antimicrobial activity of these compounds was taken
by agar dilution method against 28 pathogenic bacteria , 8 fungi and anti HIV activity
against replication of  HIV-1 in MT-4 cells. All the synthesised compounds are more
active than norfloxacin and also more active than the standard drug. Two compounds
have shown inhibition against HIV-1 with EC50 value of 11.3 and 13.9 µg/ml.
Mohammad Abid and Amir Azam 252 have discovered some novel Mannich base derivatives
(IX ) and the antiamoebic activities of these compounds were evaluated by microdilution
method  against HM1 : 1 MSS strain of Entamoeba Histolytica.
Sarvesh C. Vashishtha et al.253 have documented Mannich base and reported
them as useful anticonvulsant agent. A.L.S.Rodrigues et al.254 suggested Mannich bases
as useful antidepressant agent. Sheela Joshi et al.255 have prepared and carried out
pharmacological evaluation of novel Mannich bases derived from 5-chloro-2-methoxy
benzamido methyl sulphonamide/amine is reported and in vitro study of compounds
showed significant activities against varios pathogenic bacteria. B.Shivarama Holla
et al.256 have documented Mannich base derivatives as anticancer agent. Dheeraj
Mandloi and co-workers 257 reported Mannich base derivatives and studied their
antibacterial activity . Mohmmad Abid et al.258 have synthesised Mannich base derivatives
and subjected to evaluation for their antiamoebic activity. Compound was found to be a
better inhibitor of  Entamoeba Histolytica as compared to Metronidazole.
W.Malinka et al.259 have prepared a series of  new 4-aryl piperazine derivatives
of isothiazolo pyridine of Mannich base and assayed as potential analgesic agent.
Pharmacological  assay demonstated that all the compounds displayed significant
OHNCH3
CH3
(VIII)
N
H
Cl
S
N
CH3
CH3
(IX)
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activity in the mouse writhing assay. Ahmed S.Aborai et al.260 have synthesised a series
of 5-(2-hydroxyphenyl)-3-substituted -2,3-dihydro-1,3,4-oxadiazole-2-thione derivatives
( X) and evaluated for their in vitro anticancer activity. Seven of the investigated
compounds displayed high activity in primary assay and compounds were identified as
promising lead compounds.
Cogan P.S.et al.261 have synthesised some new Mannich base derivatives and
reported them as anticancer agent. Dharmarajan and co-worker 262 have synthesised a
series of pyrazinamide Mannich base (XI) and evaluated them for antimycobacterial
activity in vitro and in vivo against Mycobacterium Tuberculosis H37Rv. In the
in vivo animal model decreased the bacterial load in lung and spleen tissues.
Thus, the important role displayed by Mannich base derivatives for various
therapeutic and pharmaceutical activities, prompted us to synthesise some new Mannich
base in order to achieving compounds having better drug potential, this study is
described as under.
SECTION -I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-[BIS-
  ARYL/ALKYL-AMINO METHYL]-5-(o,p-DICHLOROPHENYL)-
  4-SUBSTITUTED BENZALIMINO-3-THIO-2,3-DIHYDRO-
  1,2,4-TRIAZOLES
O
N N
OH
S
R
(X)
N
N
NH N
N
Ar
O
(XI)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-[BIS-ARYL/ALKYL-
AMINOMETHYL]-5-(o,p- DICHLOROPHENYL)-4-SUBSTITUTED BENZAL
IMINO-3-THIO-2,3- DIHYDRO-[1,2,4]TRIAZOLES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of Mannich bases. To further assess the potential of such a class of
compounds, Mannich bases of type (VII) have been prepared by the condensation of
4,N-substituted benzalimino-3-mercapto-5-(o,p-dichlorophenyl)-1,2,4-triazole with
primary/secondary amines and formaldehyde in  dioxane.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Type (VI)         R = Aryl ,  R  ,R’ = Alkyl/Aryl
N N
N
N
Cl
R
Cl
S
N
R' R
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REACTION SCHEME
        Type - (VII)                   R=Aryl
N N
N
NH2
SH
Cl
Cl
R-CHO
N N
N
N
Cl
R
Cl
SH
Con. H2SO4
R-NH2 , R-NH-R'
HCHO
N N
N
N
Cl
R
Cl
S
N
R' R
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 2-[p-CHLOROANILIOMETHYL]-5-(o,p- DICHLORO
P H E N Y L ) - 4 - p -METHOXYB E N Z A L I M I N O - 3 - T H I O - 2 , 3 -DIHYDRO-
[1,2,4]TRIAZOLE
 Observed
Alkane C-H str. (asym.) 2946 2975-2950                 430
-CH3 C-H str. (sym.) 2836 2880-2860   “
C-H i.p.def. (asym.) 1466 1470-1435   “
C-H o.o.p. def. (sym.) 1367 1390-1370   “
Aromatic C-H  str. 3075 3080-3030                 431
C=C str. 1568 1585-1480   “
C-H i.p. def. 1108 1125-1090   “
C-H o.o.p. def   829  835-810   “
Triazole C=N str. 1601 1612-1593                430
moiety C-N str. 1172 1220-1020                434
N-N str. 1029 1050-1010                430
C-Cl str.   764  600-800                   432
C=S str. 1254 1250-1050                434
Ether C-O-C str. (asym.) 1213 1275-1200                430
C-O-C str. (sym.) 1029 1075-1020   “
                                              (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N N
N
N
O CH3
ClCl
SH
Cl
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 528.5 698.2
 764.7
 829.3
 960.5
1029.9
1108.0
1172.6
1213.1
1254.6
1367.4
1466.8
1569.0
1601.8
2836.1
2946.1
3075.3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 2-[p-CHLOROANILINOMETHYL]-5-(o,p-DICHLORO
P H E N Y L ) - 4 - p - M E T H O X Y B E N Z A L I M I N O - 3 - T H I O - 2 , 3 - D I H Y D R O -
[1,2,4]TRIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.85 3H singlet Ar-OCH3          -
2. 5.65 2H singlet -CH2i          -
3. 6.87-6.93 4H multiplet         Ar-Hee’,Ar-Hgg’          -
4. 7.14-7.16 2H doublet Ar-Hdd’      Jfg - 9.96
5. 7.64-7.66 2H doublet Ar-Hff’      Jgf - 8.88
6. 7.39-7.41 1H doublet Ar-Ha      Jab- 8.20
7. 7.35-7.38 1H double Ar-Hb         -
doublet
8. 7.504-7.508 1H doublet Ar-Hc      Jcb-1.80
9. 9.97 1H singlet -CHh          -
N N
N
N
Cl
Cl
S
NH
O
CH3
Cl
ab
c
d
e d'
e'
f
g
f'
g'
h
i
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-[BIS-ARYL/ALKYL-
AMINOMETHYL]- 5-(o,p- DICHLOROPHENYL)-4-SUBSTITUTED BENZAL
IMINO-3-THIO-2,3- DIHYDRO-[1,2,4]TRIAZOLES
(A) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(B) Synthesis of 4,N-substituted benzalimino-3-mercapto-5-(o,p-dichlorophenyl)-
1,2,4-triazole
See [A] Part-IV, Section-I (C)
(C) Synthes i s  o f   2-[ p-Chloroanilino methyl]-5-(o,p-dichlorophenyl)-4-
p-methoxybenzalimino-3-thio-2,3-dihydro-[1,2,4]triazoles
A mixture of 4,N-p-methoxybenzalimino-3-mercapto-5-(o,p-dichlorophenyl)-
1,2,4-triazoles (3.79 g, 0.01 M), formaldehyde (0.3 g, 0.01 M) and  p-chloroaniline
(1.28 ml, 0.01M) in dioxane(50 ml) was stirred for 24 hrs and kept overnight in a freeze.
Then the resulting mixture was poured on to crushed ice. The product was isolated and
crystllised from  ethanol. Yield 67%, m.p. 182oC (C23H18Cl3N5OS; Required :
C, 57.52; H, 4.04; N, 13.50;  Found : C, 57.70; H,4.13; N, 13.64%).
TLC solvent system : Ethyl acetate  : Hexane (2 : 3).
Similarly other derivatives have been synthesised. The physical data are recorded
in Table No. 7.
(D) Antimicrobial activity  2-[Bis-aryl/alkyl-aminomethyl]-5- (o,p-dichloro
phenyl)-4-substituted  benzalimino-3-thio-2,3-dihydro-[1,2,4]triazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 7.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that all the compounds of
type(VII) were found to be moderately active against Gram positive bacteria
B. coccus.and S. aureus, and also shown promising activity against Gram negative
bacteria like E.aerogenes and P.aeruginosa.
The maximum activity was observed in compounds bearing R=2-nitrophenyl,
4-hydroxyphenyl and 3,4-dimethoxyphenyl  against  S.aureus. The significant activity
was observed in compounds having R=2-nitrophenyl and 4-fluorophenyl  against
B.coccus.
In case of E.aerogenes all the  compounds were active and maximum activity
was shown by the compounds bearing  R=4-methoxyphenyl, 4-hydroxyphenyl and
piperidyl. The compounds having R=4-methylphenyl, 4-methoxyphenyl and
2-chlorophenyl have shown good activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited mild activity against A. niger.  While compounds
having R= 4-chlorophenyl  and phenyl shown significant activity.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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INTRODUCTION
The five membered  heterocyclic ring system 5-oxo-imidazoline have two
nitrogen atoms at the 1 and 3 position and C=0 group at following position. 2-oxo-
imidazoline (I), 4-oxo-imidazoline (II), 5-oxo-imidazoline (III).
A.W.Hoffman263, for the first time discovered 5-oxo-imidazoline by heating
N’-diacetylethylene diamine in a stream of dry hydrogen chloride. Ledenberg have prepared the
same compound by fusing two equivalents of sodium acetate with one equivalent of
ethylene diamine hydrochloride. Imidazolinones have been found to be potent drug in
pharmaceutical industries and possess a wide spectrum of biological activities.
SYNTHETIC ASPECTS
Various methods have been reported for the synthesis of imidazolinones in literature.
Aminolysis of oxazolone with amine leads to the formation of imidazolinone, which have
been reported in literature264.
1. Imidazolinones were prepared by intramolecular aza-witting reaction.
Hisato Takeuchi et al.265 have synthesised imidazolinone by the reaction of
azido substituted imides reacts with triphenylphosphine or tributylphosphine to
afford corresponding imidazolinone.
2. Jean Michel Lerestif et al.266 have prepared imidazolinone by cycloaddition
reaction with α-aminoester and imines.
(II)
N
N
H
O
1
2
34
5
N
N
H
O
N
N
H
O
(I) (III)
R3
N R1
N3 R2
O O
N R1
R2
R3
O
Ph3P or Bu3P
(IV)
130Imidazolinones....
3. Rao Y.S. and Filler R.267 have synthesised 2-arylimidazolin-5-ones by the reaction
of an oxazolone intermediate with an aryl/alkylamine.
4. Aleksey N.Vasiliev et al.268 have prepared imidazolinone by the reaction of di
ethyl ester of 5-ethyl pyridine 2,3-dicarboxylic acid with 2-amino,2,3-dimethyl
butyramide in the presence of sodium hydride.
MECHANISM
Azlactone reacts with variety of compounds such as water, alcohols, amines and
hydrogen halides. Amides of α-acylamino acrylic acids obtained from the condensation
of azalactone and primary amines can be converted into imidazolinones as shown  under.
The ring closure can be affected under a variety of conditions. Substituted anilides have
been converted to imidazolinone derivatives by the action of POCl3.
N
R1
EtO R2
MeOOC
+ N
R3
R4
N
N
R3
R1
O
R4
70 C
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O
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O
R
Ar
R'-NH2
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CH3 CH3
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N
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THERAPEUTIC IMPORTANCE
Imazapyr, (2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinic acid) a
broad spectrum herbicide of the imidazolinone family, kill plants by inhibiting  the
enzyme used when plants synthesise branched chain amino acids (BCAA). The name of
this enzyme is acetohydroxyacid syntheses. Various imidazolinones are known  to
exhibit a broad spectrum of biological activities such as.
1. Antimicrobial269
2. Antitubercular270
3. Antiviral271
4. Antiinflammatory272-274
5. Anticonvulsant275,276
6. Antiparkinsonian277,278
7. Anthelmintic279
8. Antihistaminic280
9. Anticancer281,282
10. Antidiabetic283
11. Bactericidal284,285
12. Fungicidal286,287
13. Glucagon antagonists288
14. Hypertensive289
15. Insecticidal290
16. Potent CNS depressant291,292
17. Thrombin inhibitor293
N
O
O
X
R
R'- NH2
NH
NH
X
R
O
O R'
POCl3
N
N O
R
R'X
R’-NH2, DryC5H5N/Abs. C2H5OH, K2CO3
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Zohar Y.et al.294 have discovered a novel imidazolinone containing compound,
which are useful tool in the search for new anti-TB drugs.The new anti-TB drug that
inhibit branched chain amino acid (BCAA) biosynthesis, as these are essential aminoacid
that are not available to a Mycobacterium during growth in an infected organism.
Armando Rosselo et al.295 have found that imidazolinones are potential antifungal agent.
Mimi L.Quan et al.296 have discovered biphenyl imidazolinone derivatives.
Representative compounds (IX) were very active in lowering blood pressure in conscious
renal hypertensive rats and also useful as angiotensin II receptor antagonist.
Rama Sharma and co-workers297 have formulated 5-oxo-imidazolines possessing
potential antimicrobial activity. Keun-Jin Oh et al.298 have investigated some novel
imidazolinone derivatives, which abolised the enzymatic activity as well as the binding
affinity for the co-factor FAD (Flavin,Adenine Dinucleotide). Menn JJ299 have
synthesised imidazolinone derivatives and used as pesticides.
George V De Lucca300 have reported imidazolinone derivatives, which  are shown
to possess excellent HIVprotease inhibitor activity. Jean M.R.et al.301 have discovered
imidazolinones and tested as antileishmanial agents. Irene M.L. et  al.302 have investigated
some imidazolinone derivatives possessing antireteroviral activity. Kalluraya B. and
co-workers303 have discovered a series of 4-(1-aryl-5-oxo-2-phenyl-2-imidazolin
-4-yl)methano-5-chloro-3-methyl-1-phenyl-3-pyrazole and tested for their
anti-inflammatory, analgesic and antibacterial activity. A series of  imidazolinone analogues
was synthesised and shown to possess potent murb inhibitory as well as antibacterial
activity by Bronson J.J et al.304. Solankee A.et al.305 have synthesised some
imidazolinone derivatives (X) and evaluated them as antitubercular agent.
N
N
AR1
CH3
CH3
O
(IX)A=tetrazole
133Imidazolinones....
El-Sayed A.S.et al.306 has synthesised imidazolinone derivatives (XI) and
screened for their antibacterial and antifungal activities. Wang J.G et al.307 have reported
imidazolinones as herbicides. Aleksey N. Vasiliev et al.308 have synthesised
imidazolinone (XII) and studied their herbicidal activity.
Trucco F. et al.309 have prepared imidazolinones, which are used in
acetolactate synthase (ALS) catalyses, the first common step in the biosynthesis of
branched chain amino acid in plant and is the target of several herbicides. Quivet E.
et al.310 have synthesised (2-(4-isopropyl-4-methyl)-5-oxo-2-imidazolin-2-yl)-nicotinic
acid, a broad spectrum herbicide of the imidazolinone family and Quivet also synthesised
its metal salt and increased stability and herbicidal activity. Tan S. and Evan R.311 have
reported imidazolinones as useful herbicides.
CONTRIBUTION FROM OUR LABORATORY
 Dr. H. H. Parekh et. al.312 suggested imidazolinones as a antitubercular,
anticancer (XIII) agents.
N
N
N
N
O
Ph
CH3CH3
Ph
OAr
(X)
O
O2N
N
N
O
SO2NHR1
R
(XI)
N
N
H
N
O
CH3
CH3
CH3
COOHR
R'
(XII)
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H. H. Parekh and co-workers313 have synthesised 5-oxo-imidazolines as novel
bioactive compounds derived from benzimidazole. P. H. Patel and co-workers314 have
discovered imidazolines bearing 2-amino-thiazole moiety as an antimicrobial agents.
A. R. Parikh315 have reported 5-oxo-imidazolines as biologically active agents. Hasmukh
Kanjaria and co-workers316 have described imidazolinones as potential antimicrobial
agents. Satyen P. Patel and co-workers317 have synthesised imidazolines as biologically
active agents.
Joshi H. et. al.318 have synthesised imidazolinones as potent anticonvulsant
agents. Parikh et. al.319 have reported 4-(4’-arylidene-2’-phenyl-5’-oxo-imidazolin-
1’-yl)- benzophenone and screened for their antimicrobial activity.
With a view to getting better therapeutic agent, we have synthesised novel
imidazolinones to enhance the overall activity of resulting compounds, which have been
described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1[3’-
 MERCAPTO-5’-(o,p-DICHLOROPHENYL) -TRIAZOL-4’-
 YL]-2-PHENYL-4-ARYLIDINE-5-OXO-IMIDAZOLES
N
N
NH NH
S
OO
CH3
O
CH3
Ar
(XIII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1 [ 3 ’ - M E R C A P T O - 5 ’ -
( o, p- DICHLOROPHENYL) -TRIAZOL-4’-YL]-2-PHENYL-4-ARYLIDINE-5-
OXO-IMIDAZOLES
Imidazolinone derivatives possess various of biological and pharmacological
properties. Here, we report the synthesis of some new 5-oxo-imidazolines of type (VIII).
The strategy employed for the synthesis of desired compounds involved the condensation
of 3-mercapto-4,N-amino-5-(o, p-dichlorophenyl)-1,2,4-triazole  with different azlactones
in pyridine.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
.
Type (VIII)                R = Aryl
N N
N
Cl
Cl
SH
N
N
O
R
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REACTION SCHEME
        Type - (VIII)                   R=Aryl
N N
N
NH2
SH
Cl
Cl
R-CHO
N N
N
Cl
Cl
SH
N
N
O
R
+
O
NH
O
OH
CH3COONa
(CH3CO)2O
N
R
O
O
+
Pyridine
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
I R  S P E C T R A L  S T U D Y  O F  1 [ 3 ’ - M E R C A P T O - 5 ’ - ( o , p - D I C H L O R O
PHENYL)-TRIAZOL-4’-YL]-2-PHENYL-4-p-METHYL BENZYLIDINE-5-OXO-
IMIDAZOLE
 Observed
Alkane C-H str. (asym.) 2920 2975-2950  430
-CH3 C-H str. (sym.) 2850 2880-2860   “
C-H i.p.def. (asym.) 1492 1470-1435   “
C-H o.o.p. def. (sym.) 1352 1390-1370   “
Aromatic C-H  str. 3047 3080-3030  431
C=C str. 1596 1585-1480   “
C-H i.p. def. 1089 1125-1090   “
C-H o.o.p. def  829  835-810   “
Triazole C=N str. 1639 1640-1605  434
moiety C-N str. 1166 1220-1020  430
N-N str. 1008 1050-1010  434
C-Cl str.  682 600-800  433
Imidazolinone -C=O str. 1720 1760-1655  432
C=N str. 1639 1640-1500  434
                                                (overlapped)
C-N str. 1070 1220-1020  430
Ether C-O-C str. (asym.) 1230 1275-1200   “
C-O-C str. (sym.) 1008 1075-1020   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N N
N
N
Cl
N
O
Cl
SH
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 1[3’-MERCAPTO-5’-(o,p- DICHLOROPHENYL)-
TRIAZOL-4’-YL]-2-PHENYL-4-p-METHYL BENZYLIDINE-5-OXO-IMIDAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.90 1H singlet Ar-OCH3                -
2. 6.99-7.02 2H            doublet           Ar-Hdd’              Jde-8.84
3. 7.23-7.26 1H doublet Ar-Hee’              Jab - 8.79
4. 7.50-7.62 3H multiplet Ar-Ha,Ar-Hb        -
    Ar-Hc
5. 8.16-8.22 6H multiplet          phenyl + CHi        -
N N
N
Cl
Cl
SH
N
N
O
O
CH3
a
b
c
f
f'
g
g'de
d'e'
h
i
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EXPANDED AROMATIC REGION
N N
N
Cl
Cl
SH
N
N
O
O
CH3
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c
f
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g
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d'e'
h
i
N N
N
Cl
Cl
SH
N
N
O
CH3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1 [ 3 ’ - M E R C A P T O - 5 ’ -
( o, p- DICHLOROPHENYL) -TRIAZOL-4’-YL]-2-PHENYL-4-ARYLIDINE-5-
OXO-IMIDAZOLES
(A)  Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(B) Synthesis of 2-Phenyl-4-(p-methoxy benzylidine)-oxazolin-5-one
A mixture of p-methoxybenzaldehyde(1.36 g,0.01M), acetic anhydride
(7.6ml, 0.075M), sodium acetate (2.0 g, 0.025M) and hippuric acid (4.4g, 0.025M)
was heated on waterbath for 4 hrs. Resulting mass was poured onto crushed ice,
filtered, washed with hot water and crystallised from ethanol. Yield 68%, m.p. 145oC,
(C16H13NO3 : Required C : 73.11; H : 4.69; N : 5.02; Found C : 73.18; H : 4.75; N :
5.09%).
TLC solvent system : Ethylacetate : Hexane (2 : 8)
(C)  Synthesis of 1[3’-Mercapto--5’-(o,p-dichlorophenyl)-triazol-4’-yl]-2-phenyl-
4-p-mehoxybenzylidine-5-oxo-imidazoles
A mixture of  2-phenyl-4-(p-methoxybenzylidine)-oxazolin-5-one (2.79 g, 0.01M)
and 3-mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole (2.60g, 0.01M) in dry
pyridine (20 ml) was refluxed for 12 hrs. Resulting mass was poured on to crushed ice
and neutralised with HCl, filtered and crystallised from ethanol. Yield,  65%, m.p. 160oC
(C25H17Cl2N5O2S : Required C: 57.48; H: 3.28; N: 13.41; Found : C: 57.40; H:
3.34; N: 13.52%).TCL solvent system : Acetone : Benzene (2 : 8).
Similarly other imidazolin-5-ones have been prepared. The physical data
are recorded in Table No. 8.
(D)  Antimicrobial activity of 1[3’-Mercapto--5’-(o,p-dichlorophenyl)-triazol-4’-yl]-
2-phenyl-4-arylidine-5-oxo-imidazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 8.
142Imidazolinones....
   
 S
r.
   
 R
  M
ol
ec
ul
ar
   
M
ol
ec
ul
ar
   
   
M
. P
.
   
   
  R
f*
   
 Y
ie
ld
   
  %
 o
f N
it
ro
ge
n
   
 N
o.
   F
or
m
ul
a
   
  W
ei
gh
t
   
   
  o
C
   
   
V
al
ue
   
   
%
   
   
   
   
C
al
cd
.  
   
   
Fo
un
d
1
   
 2
   
   
 3
   
   
   
4
   
   
   
5
   
   
   
6
   
   
   
   
   
  7
   
   
   
   
   
 8
   
   
 9
TA
B
L
E
-8
 :
PH
Y
SI
C
A
L 
C
O
N
ST
A
N
T
S 
O
F 
 1
[3
’-M
ER
C
A
PT
O
-5
’-(
o,
p-
D
IC
H
LO
R
O
PH
EN
Y
L)
 -T
R
IA
ZO
L-
4’
-Y
L]
-2
-P
H
EN
Y
L-
4-
A
R
Y
LI
D
IN
E-
5-
O
X
O
-I
M
ID
A
Z
O
L
E
S
*T
LC
 S
ol
ve
nt
 S
ys
te
m
 : 
A
ce
to
ne
 : 
B
en
ze
ne
 (2
 : 
8)
8a
4-
O
C
H
3-
C
6H
4-
C
25
H
17
C
l 2
N
5O
2S
   
52
2.
40
 1
60
0.
69
65
   
13
.4
1
   
  1
3.
52
8b
3-
N
O
2-
C
6H
4-
C
24
H
14
C
l 2
N
6O
3S
  5
37
.3
7
 1
00
0.
64
68
   
15
.6
4
   
  1
5.
69
8c
4-
O
H
-C
6H
4-
C
24
H
15
C
l 2
N
5O
2S
   
50
8.
38
 1
80
0.
80
72
   
13
.7
8
   
  1
3.
86
8d
3-
B
r-
C
6H
4-
C
24
H
14
B
rC
l 2
N
5O
S
   
57
1.
27
 1
40
0.
72
55
   
12
.2
6
   
  1
2.
41
8e
4-
C
l-
C
6H
4-
C
24
H
14
C
l 3
N
5O
S
   
52
6.
82
 1
44
0.
68
67
   
13
.2
9
   
  1
3.
39
8f
4-
C
H
3-
C
6H
4-
C
25
H
17
C
l 2
N
5O
S
   
50
6.
40
 1
20
0.
75
69
   
13
.8
3
   
  1
3.
91
8g
2-
N
O
2-
C
6H
4-
C
24
H
14
C
l 2
N
6O
3S
   
53
7.
37
 1
70
0.
81
70
   
15
.6
4
   
  1
5.
77
8h
2-
O
H
-C
6H
4-
C
24
H
15
C
l 2
N
5O
2S
   
50
8.
38
 1
80
0.
73
58
   
13
.7
8
   
  1
3.
87
8i
9-
C
14
H
9-
C
32
H
19
C
l 2
N
5O
S
   
59
2.
49
 1
52
0.
77
62
   
11
.8
2
   
  1
1.
89
8j
3,
4-
(O
C
H
3)
2-
C
6H
3-
C
26
H
19
C
l 2
N
5O
3S
   
55
2.
49
 1
20
0.
72
68
   
12
.6
8
   
  1
2.
74
8k
4-
F-
C
6H
4-
C
24
H
14
C
l 2
FN
5O
S
   
51
0.
37
 1
68
0.
84
63
   
13
.7
2
   
  1
3.
82
8l
2-
C
l-
C
6H
4-
C
24
H
14
C
l 3
N
5O
S
   
52
6.
82
 2
10
0.
64
65
   
13
.2
9
   
  1
3.
46
143Imidazolinones....
051015202530
ZONE OF INHIBITION IN mm B.
 c
oc
cu
s
17
17
16
16
19
17
19
21
18
24
23
19
25
18
20
22
0
S.
 a
ur
eu
s
16
23
22
17
21
19
18
16
18
19
17
14
25
19
15
21
0
E.
ae
ro
ge
ne
s
20
17
14
18
20
18
16
21
19
17
14
18
20
21
22
19
0
P.
ae
ru
gi
no
sa
19
18
15
16
18
21
17
19
18
18
21
16
22
21
16
23
0
A
. n
ig
er
18
21
23
17
18
16
21
19
17
14
18
19
0
0
0
0
26
8a
8b
8c
8d
8e
8f
8g
8h
8i
8j
8k
8l
A
m
ox
ic
ill
in
Be
nz
oy
lp
e
ni
ci
lli
C
ip
ro
flo
xa
c
in
Er
yt
h
ro
m
y
ci
n
G
re
s
eo
fu
l
vi
n
G
R
A
PH
IC
A
L 
C
H
A
R
T
 N
O
. 8
 :
  
A
N
T
IM
IC
R
O
B
IA
L
 A
C
T
IV
IT
Y
 O
F
 1
[3
’-
M
E
R
C
A
P
T
O
-5
’-
(o
,p
-
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
D
IC
H
L
O
R
O
PH
E
N
Y
L
) -
TR
IA
ZO
L-
4’
-Y
L
]-
2-
PH
E
N
Y
L
-4
-A
R
Y
L
ID
IN
E
-5
-O
X
O
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 -
IM
ID
A
Z
O
L
E
S
144Imidazolinones....
CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been observed that all the compounds of
type (VIII) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having R= 2-hydroxy
phenyl, 3,4-dimethoxyphenyl and 4-fluorophenyl against B.coccus. The compounds
bearing R= 4-chlorophenyl,4-hydroxyphenyl and 3-nitrophenyl have highly inhibited the
growth of S.aureus.
Compounds with R= 4-chlorophenyl,4-methoxyphenyl and 2-hydroxyphenyl
showed significant activity against E.aerogenes. While the compounds bearing
R=4-methylphenyl and 4-fluorophenyl  fairly inhibited the growth of P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were active against A.niger. Maximum activity was observed
by the compounds bearing R= 2-nitrophenyl  and  4-hydroxyphenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.

145Nitriles....
INTRODUCTION
Nitriles represent an important class of chemical substances that have broad
spectrum of biological activities. The term nitrile was first introduced by Febung320 in
1844. The first synthesis of nitrile has been reported by Wholer and Liebig321. They
are very much useful as intermediate for various products, such as acrylonitrile for plastic,
synthetic rubber and fiber, phthalonitrile for dye stuff.
                    Industrially, nitriles are formed by heating carboxylic acids with ammonia
and dehydration under pressure. For the preparation of acrylonitrile, which is used in a
large scale in the plastic industry, a vapour-phase catalytic ammoxidation of propylene
has been devoloped. For a structurally simple group of compounds, modified nitriles
have displayed an impressive array of biological activities.
SYNTHETIC  ASPECTS
Few recent methods for the preparation of nitriles are as mentioned below.
1. E.A. Letts322 has synthesized nitriles by the condensation of aromatic acids
with metal thiocyanates .
2. Stephen A. Dibiase et al.323 have synthesised E- & -Z cinnamonitrile from aryl
aldehyde or ketones in presence of acetonitrile and potassium hydroxide.
3. Biswanath Das et al.324 have prepaid nitriles from aryl/alkyl aldehydes on
treatment with NH2OH.HCl under microwave irradiation in presence of NaHSO4/
SiO2/Hy-Zeolite or silica chloride.
Ar-CHO
Ar
N
CH3CN
KOH
(II)
Ar-COOH+ KSCN R-CN+ CO2 + KHS
(I)
R-CHO
NH2OH.HCl
Catalyst
R-CN
(III)
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4. Weissman S.A et al 325 have  prepared nitriles with the use of as little as 0.1
mol%Pd(OAC)2 with non toxic cyanide source K4[Fe(CN)6] .
5. Barahman Movassagh and Salman Shokri326 have prepared nitriles from aryl/
alkyl aldehydes on treatment with NH2OH.HCl and KF/Al2O3 in one pot.
6. Masanori  and Masahiko327 have synthesised nitriles through cyanation of
aryl/heteroaryl bromides employing heterogeneous Pd/C.
MECHANISM
The Mechanism of nitrile is shown as under.
Reaction between CN and aldehyde is a type of nucleophilic substitution reaction.
From the above reaction, it can be seen that a nucleophile (CN) attacks on the carbonyl
carbon of aldehyde and yields cyanohydrin which reacts with amine to yield nitrile
derivative.
R-CHO
NH2OH.HCl, KF/Al2O3
DMF/ 100 C
R-CN
R = Alkyl or aryl(V)
Ar-Br + Zn(CN)2
Pd/C, Zn, ZnBr2, PPh3
DMA
Ar-CN
(VI)
Br CN
(IV)
0.1 mol %Pd(OAC)2
0.22 eq K4[Fe(CN)6]
O
H
R
+ CN
O
CN
R
H
OH
CN
H
R
R1-NH2
-H2O
NH
CN
H
R
R1
H+
. .
_
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THERAPEUTIC IMPORTANCE
Nitrile derivatives exhibit broad spectrum of therapeutic activity. Several
biological activities associated with nitrile derivatives have been described as under.
1. Antimalarial 328
2. Antimicrobial 329
3. Antihypertensive330
4. Antihypoxic331
5. Antiinflammatory332
6. Antiarrythmetic333
7. Fungicidal334
8. Pesticidal335
9. Cathepsin K inhibitor336
10. Anticonvulsant337
11. Central nervous system agent338
Itoh H. and co-workers339 discovered the new series of 2-aryl-3-(1H-1,2,4-
triazol-1-yl) propanenitrile and reported them as fungicidal. These derivatives exhibited
higher efficacy than reference fungicides. Norsyrava et.al.340 have formulated novel
nitriles possessing muscle relaxant activity. Cutri C.C.C et al.341 documented 3-
methylthio-5-(4-bromophenyl)-4-isothiazole carbonitrile and studied their antiviral
activity. Parlo Sanna   et al.342 have synthesised nitrile (VII) and screened for their
antituberculur activity.
Volvenko Yu M.et al.343 have prepared α- substituted (5-trifluoromethyl-
2-pyridyl) acetonitriles and evaluated for their antimicrobial, diuretic and cytotoxic activity.
Bernard M.et al.344 have investigated nitriles as thromboxane receptor antagonists.
N
N
N
N
NH2
(VII)
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The development of new antimalarial drug is an urgent priority considering the increasing
prevalence of drug resistant plasmodium falciparum parasites. Some novel nitrile
derivatives which are effected on malaria is synthesised by Dominguez J.N.et al.345
Boschelli D.H.et al.346 have prepared a series of 4-anilino-7-thienyl-3-quinolino
carbonitrile and identified its Src Kinase inhibitor activity. Iwanowicz  E .J. et al.347
have synthesised nitriles(VIII) and found preventing and treating IMPDH associated
disorders.
Murakkami.Hiroshi et al.348 have investigated some new nitriles and studied
their pesticidal and marin antifouling activity. Miroslav Otmar et al.349 have formulated
nitriles possessing antiproliferetive activity. Saczewski F.et al.350 have synthesised many
acetonitriles substituted at position-2 with either triazoles or benzimidazoles and tested
for in vitro cytotoxic potency on 11 human cancer cell line.
Dynamin I is a G T phase enzyme required for endocytosis and is an excellent
target for the design of potential endocytosis inhibitor. Hill T. et al.351 have discovered
the nitriles which are very useful as endocytosis inhibitor. Ian J.S.Fairlamb et al.352
have prepared nitrile derivatives and tested for their antimicrobial activity.
CONTRIBUTION FROM OUR LABORATORY
 F.M.Bharmal and H.H.Parekh353 have synthesised newer acetonitriles (IX)
bearing quinoline moiety and tested them as an antimicrobial agent.
N N
N
NH2
S
CH3
N(VIII)
N
CH3
Cl
NH
R
N
(IX)
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Recently, Kiderlen D et al.354 have discovered some novel nitriles and evaluated
them as cathepsin K inhibitor. Altmann E.et al.355 have documented novel acetonitriles
as cathepsin K inhibitor. F.Saczewski et al.356 have synthesised a series of 2-(4,6-
diamino-1,3,5-triazin-2-yl)-2-{[4,6-(dimethylamino)-phenyl]imino}acetonitriles (X), (XI)
and checked their in vitro anticancer activity. Most of the compounds show remarkable
activity against melanoma MALME-3 M cell line.
The development of efficient and selective synthesis by structural modification of
nitriles have attracted increasing attention over the last several years,because they often
bring about unique physiological properties. These findings encouraged us to search
some novel nitrile derivatives.
SECTION-I :  SYNTHESIS AND BIOLOGICAL EVALUATION OF á-ARYL-
   [3-MERCAPTO-5-(o,p-DICHLORO PHENYL)-1,2,4-TRIAZOL - 4’-YL]
  -AMINO ACETONITRILES.
N
N
N
CH2CN
R NH2
N
N
N
R NH2
N
CH3
N(CH3)2
(XI)(X)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYL [ 3 -
M E R C A P T O - 5 - (o,p- DICHLOROPHENYL) -1,2,4-TRIAZOL-4’-YL]-AMINO
ACETONITRILES
Recently, much interest has been focused on the synthesis and biodynamic
activities of nitriles. With an intention for preparing agent with better therapeutic potency,
the nitriles of type-(IX) have been synthesised by the reaction of  3-mercapto-4,N-amino-
5-(o,p-dichlorophenyl)-1,2,4-triazole  with  different aromatic aldehydes in the presence of
potassium cyanide and glacial acetic acid at 0-50C.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
.
Type (IX)                R = Aryl
N N
N
NH
SH
Cl
Cl
N
R
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        Type - (IX)                   R=Aryl
N N
N
NH2
SH
Cl
Cl
O
NH NH2
Cl
Cl
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
NH
SH
Cl
Cl
N
R
R-CHO
KCN
gl.CH3COOH
0-5 C
REACTION SCHEME
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 
 α-(4-METHOXYPHENYL)-[ 3 - M E R C A P T O - 5 -
(o,p- DICHLOROPHENYL) -1,2,4-TRIAZOL-4’-YL]-AMINO ACETONITRILE
Alkane C-H str. (asym.) 2920 2975-2950 430
-CH3 C-H str. (sym.) 2866 2880-2860   “
C-H i.p.def. (asym.) 1454 1470-1435   “
C-H o.o.p. def. (sym.) 1357 1390-1370   “
Aromatic C-H  str. 3033 3080-3030  431
C=C str. 1554 1585-1480   “
C-H i.p. def. 1105 1125-1090   “
C-H o.o.p. def  815  835-810   “
Triazole C=N str. 1600 1612-1593  434
moiety C-N str. 1271 1350-1200  430
N-N str. 1062 1050-1010  434
C-Cl str.  759  600-800  433
Ether C-O-C str. (asym.) 1217 1275-1200  430
C-O-C str. (sym.) 1012 1075-1020   “
Nitrile C≡N str.                                      2237 2240-2000  434
N-H str 3332 3450-3200   430
N-H def 1600 1650-1580    “
                                            (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
N
NH
SH
O CH3
Cl
Cl
N
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/it il f h3 ( d )
 439.7
 522.7
 605.6
 692.4
 740.6
 759.9
 815.8
 844.8
 920.0
 958.6
1012.6
1062.7
1126.4
1155.3
1217.0
1271.0
1357.8
1413.7
1454.2
1502.4
1515.9
1554.5
1600.8
2237.3
2866.0
2920.0
3033.8
3332.8
 Observed
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 
 α-(4-METHOXYPHENYL)-[ 3 - M E R C A P T O - 5 -
(o,p- DICHLOROPHENYL) -1,2,4-TRIAZOL-4’-YL]-AMINO ACETONITRILE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.85 3H singlet Ar-OCH3          -
2. 4.91 1H singlet -CHf          -
3. 6.92-6.95 2H doublet Ar-Hdd’ Jde- 8.73
4. 7.62-7.65 2H doublet Ar-Hee’ Jed- 8.69
5. 7.81-7.82 1H doublet Ar-Hc Jcb- 2.64
6. 6.84-6.88 1H double Ar-Hb         -
doublet
7. 8.33-8.36 1H doublet Ar-Ha Jba- 8.71
8. 10.1 1H singlet -NHg          -
9. 11.0 1H singlet -SHh          -
N N
NCl
Cl
NH N
SH
O
CH3
ab
c
d
e
d'
e'
f
g
h
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EXPANDED AROMATIC REGION
N N
NCl
Cl
NH N
SH
O
CH3
ab
c
d
e
d'
e'
f
g
h
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF α -ARYL [ 3 -
M E R C A P T O - 5 - (o,p- DICHLOROPHENYL) -1,2,4-TRIAZOL-4’-YL]-AMINO
ACETONITRILES
(A) Synthesis of Potassium o,p-dichlorobenzoyl dithiocarbamate
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of α− (p-Methoxyphenyl)-[3-mercapto-5-(o,p-dichlorophenyl)-
1,2,4-triazol- 4’-yl]-amino-acetonitrile
p-Methoxybenzaldehyde (1.36 g, 0.01M) dissolved in ethanol (25ml) was added
to potassium cyanide (0.64g, 0.01M) dissolved in water (18 ml) followed by glacial
acetic acid (12 ml). The contents were then stirred for 5 minutes to form cyanohydrin at
0oC. 3-Mercapto-4,N-amino-5-(o,p-dichlorophenyl)-1,2,4-triazole (2.60 g, 0.01M)
dissolved in ethanol was added to the reaction mixture , contents were stirred at room
temperature for 24 hrs. The content was poured onto curshed ice. The solid product was
filtered and crystallised from ethanol. Yield 53%, m.p. 175oC (C17H13Cl2N5OS;
Required : C, 50.26; H, 3.23; N, 17.24;  Found : C, 50.35; H, 3.31; N, 17.36%).
TLC solvent system : Ethyl acetate : Hexane (3 : 2)
Similarly other substituted nitriles have been prepared. The physical data are
recorded in Table No. 9.
(E) Antimicrobial activity of α−Aryl-[3-mercapto-5-(o,p-dichlorophenyl)-
1,2,4-triazol- 4’-yl]-amino-acetonitriles
Antimicrobial testing was carried out as described in [A] Part-I, section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 9.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=4-methylphenyl, 4-chlorophenyl and 2-chlorophenyl have displayed good activity
against B.coccus. The compounds bearing R=3,4-dimethoxyphenyl and  3-hydroxyphenyl
have shown considerable activity against S.aureus.
In case of  Gram negative bacterial strains,  the significant activity was display by
the compound bearing R=3-bromophenyl and 3-nitrophenyl against E.aerogenes. While
the compounds bearing R=4-methylphenyl and 2-chlorophenyl showed better activity
against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds displayed good activity against the tested species. However,
the compounds having R=3-nitrophenyl  and 3, 4-dimethoxyphenyl displayed highest
activity against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared with
standard drug viz. greseofulvin.

160Dihydro pyrimidines....
INTRODUCTION
Pyrimidine is the most important member of all the diazines as this ring system
occurs widely in living organisms. Purines, uric acid, barbituric acid and anti-malarial
and antibacterial agents also bear the pyrimidine skeleton. The chemistry of pyrimidine
has been widely studied. Pyrimidine was first isolated by Gabriel and Colman in 1899.
Despite the importance of dihydroazines (particularly those containing the 1,4-
dihydropyrimidine and dihydropyridine moiety)357 for clarifying a wide range of theoretical,
medicinal and biological problems, the chemistry of this group of compounds is still
extremely spotty. 358-362
In the area of drug development, dihydroazines show great promise, particularly
since the 4-aryldihydropyridines exhibit powerful vasodilation activity via modifying the
calcium ion membrane channel.363-367  Additionally, dihydropyridines have been found
active to transport medication across biological membranes.368
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
This lacuna has motivated our deep involvement in developing dihydropyrimidine
chemistry, particularly dihydropyrimidines containing no substituents on the ring
nitrogen.369  These molecules have long been considered unstable for oxidation,
polymerization or disproportionation reactions.370
Figure (I) depicts the five possible isomeric structures of dihydropyrimidines,
exhibiting different dispositions of the double bonds.
N
N
H
N
N
H
N
N
H
N
N
N
N
A B C D E
(I)
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With an emergence of high throughput screening in the pharmaceutical industry
over a decades ago synthetic chemist were faced with the challange of preparing large
collections of molecules to satisfy the demand for new screening compounds. The unique
exploratory power of  multicomponent reaction was soon recognised to be extremely
valuable to produce compound libraries in a time and cost effective manner.
Multicomponent reactions (MCRs) are of increasing importance in organic and medicinal
chemistry. In times were a premium is put on speed, diversity and efficiency in the drug
discovery process. MCRs strategies offer significant advantages over conventional
linear-type syntheses. In such reactions, three or more reactants come together in a
single reaction vessel to form a new product that contain portions of  all the
components. In an ideal case, the individual building blocks are commercially available
or are easily synthesised, and cover a broad range of structural variations. Multicomponent
reactions leading to interesting heterocyclic scaffolds are particularly useful for the
creation of    diverse  chemical libraries of “drug-like” molecules for biological screening,
since the combination of  three or more small molecular weight building blocks in a single
operation leads to high combinatorial efficacy.
One prominent MCRs that produces an interesting class of nitrogen heterocycles
is the venerable Bigineli dihydropyrimidine synthesis. In 1893, P.Biginelli reported on
the acid catalysed cyclocondensation reaction of ethyl acetoacetate, benzaldehyde and
urea. The reaction was carried out by simply heating a mixture of the three components
dissolved in ethanol with a catalytic amount of HCl at reflux temperature. The product
of this novel one-pot, three component synthesis that precipitated on cooling of the
reaction mixture was identified as 3,4-dihydropyrimidin-2(1H)-one, and this reaction is
nowadays referred to as “Biginelli reaction”, “Biginelli condensation” or as “Biginelli
dihydropyrimidine synthesis”.
In recent years, interest has been  also focused on aza-analogues such as
dihydropyrimidines (DHPMs), which show very similar pharmacological profile to
classical dihydropyridine calcium channel modulators.
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SYNTHETIC ASPECTS
1. In 1893 Pietro Biginelli reported the first synthesis of dihydropyrimidines
by a simple one-pot condensation reaction of ethyl acetoacetate, benzaldehyde
and urea under strongly acidic condition371,372.
2. DHPM-2(1H)-ones were prepared in high yield by Biginelli condensation
of an aldehyde, a dicarbonyl compound and urea in ethanol using Mn(OAc)3
as a catalyst.373
3. Substituted 3,4-DHPM-2(1H)-ones were prepared in high yield by Biginelli
condensation of an aldehyde, dicarbonyl compound and urea in ethanol
using CoCl2.6H2O catalyst.374
4. Subhas D. Bose et al.375 describe a general and practical route for the Biginelli
cyclocondensation reaction using cerium(III) chloride (CeCl3)heptahydrate as catalyst.
5. A simple effective synthesis of DHPM-2-(1H)-one derivatives, using boric acid
as a catalyst from an aldehyde 1,3-dicarbonyl compound and urea in glacial
acetic acid is described by Tu Shujang et al.376 Compared with the classical
Biginelli reaction conditions, this new method has the advantage of excellent yield
86-97% and the short reaction time (0.5-2hr).
6. Silica sulfuric acid efficiently catalyses the three component Biginelli reaction
between an aldehyde, α,β-cabonyl compound, and thiourea in ethanol  to afford
the corresponding dihydropyrimidines (III) in high yield by Salehi Peyman et al..377
The catalyst is reusable and can be applied several times without any decrease in
the yield of the reaction.
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
O
H
+ NH
N
H
Ph
OCH3
EtOOC
(II)
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7. DHPM was prepared from three component β-diketone, aldehyde and thio
urea coupling in ethanol catalyse by indium(III) tribromide(InBr3).378,379
  This
modified one-pot Biginelli condensation provided not only simple preparation
but also this modified Biginelli reaction was oxygen-bridge.
8. Ethyl 1-methyl-2-(methylthio)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylate has
been investigated by M.A.Hassan et al.380 by the reaction of 5-carboethoxy-
2-thiouracil, methyl iodide with the use of tetra butylammonium bromide (PTC)
as catalyst with continuous efficient stirring for 4-6 hrs at 700C.
MECHANISM
Despite the importance and current interest in dihydropyrimidines of (V), the
mechanism of the classical three-component Biginelli condensation has not been
elucidated with certainty and remains disputed.381
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
S NH
N
H
Ph
SCH3
EtOOC
Silica H2SO4
(III)
N
NH
SH
O O
O CH3
N
NH
H3CS
O O
O CH3TBAB  ,CH3I
Stirring  4-6 h
(IV)
CH3 O
O
EtO
+
O H NH2
NH2 O
NH
N
H
O
O
CH3
EtO
H
+
EtOH
     (V)
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The “carbenium ion mechanism” was proposed by Sweet and Fissekis,382 who
investigated the reaction in 1973 and suggested that an acid-catalysed aldol condensation
is the first and limiting step of the Biginelli condensation. It was proposed that under
acid catalysis benzaldehyde  and ethyl acetoacetate would react in an aldol-type fashion
to produce the corresponding aldol, which dehydrates in the presence of acid to the
resonance-stabilized carbenium ion.383(1)
Interception of cation (1) by urea or N-methylurea then produces ureides (2),
which ultimately cyclise to the Biginelli products. (3)
New drug molecules under clinical study
Recently many new molecules which are under study from phase-I to Phase-IV clinical
trials for different pharmacological action have shown that the basic characteristic of
morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
CH3 O
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Ph-CHO
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+
CH3 O
EtOOC
OH
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H2O
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NH2
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R H
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CH3
O
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ONH
R
-H2O
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N
R
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EtOOC
CH3 O
2a; R=H
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3a; R=H
3b; R=Me
1
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N
H
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O
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Calcium Channel Blockers384
Company Name: Merck & Co.
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Flucytosine
(fluorocytosine)
Antifungal Agent.386 Immunosuppressants
Oncolytic Drug
        (VIII)      (IX)
N
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S
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O
O
CH3
TNK-6123
TNK-6123
Anti HIV Agent
Reverse Transcripase Inhibitor.
Non-nucleoside HIV-1 reverse t ran-
scriptase inhibitor
Compound was active not only against
wild-type HIV-1 strains (IC50 = 3 nM
against IIIB and NL4-3 HIV-1 strains).
          (X)
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THERAPEUTIC IMPORTANCE
Atwal K. S. et al.387 have described  the potent antihypertensive activity of the
modestly active (ICw = 3.2 pM) dihydropyrimidine calcium channel blocker. Kappe C.
O. et al.388 synthesised the polycyclic DHPM derivatives. T. G. Muralidhar et al.389
have synthesised several DHPM-one analogues, among this (XI) and (XII) gave excellent
selectivity (>880-fold) over α1b and α1d and also showed good selectivity over
several other recombinent human G-protein coupled receptors.
Victor E. M.et al.390synthesised 5’-triphosphates of (XIII) and (IVX) evaluated
directly as reverse transcriptase(RT) inhibitors using both a recombinent enzyme and
enzyme obtained and purified directly from wild-type viruses.
Sanjay Batra et al.391 have synthesised 5-arylmethyl-4-imino-3-aryl-3,4-
dihydro-1H pyrimidin-2-ones which were tested for their antibacterial activity.
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Mai A. and co-workers392 have investigated the dihydropyrimidines which are
highly active against HIV-1. Herve Ganeste and co-workers393 synthesized substituted
1H-pyrimidin-2-one with selective dopamine D3-receptor antagonists activity. Biginelli
compound shows a diverse range of biological activities. As early as 1930 simple
derivatives of (XV) were patented as agent for the protection of  wool against moths by
Dondoni A et al.394 Later, interest focused on the antiviral activity of Biginelli
compounds.395
Pyrimidine-5-carboxamides derivatives of (XVI) were reported to possess
anticarcinogencic activity,396 antiinflammaroty,397 analgesic398 and blood platelet
aggregation inhibitory activity. 399
A very recent highlight in this context has been the identification of the structurally
rather simple DHPM monastrol (XVII) as a novel cell-permeable molecule that blocks
normal bipolar spindle assembly in mammalian cells and therefore causes cell cycle
arrest.400  Haggarty S. J. et al.401 suggested that monastrol specifically inhibites the
mitotic kinesin Eg5 motor protein and can be considered as a new lead for the
development of anticancer drugs.  George C.et al.402 prepared dihydropyrimidine
(XVIII), was equipotent to nifedipine and amlodipine in vitro. In the spontaneously
hypertensive rat, dihydropyrimidine (XVIII) is both more potent and longer acting than
nifedipine and compares most favourably with the long-acting dihydropyridine derivative
amlodipine. Dihydropyrimidine (XVIII) has the potential advantage of being a single
enantiomer.
NH
N
H
SCH3
H
O
OCH3
Cl
NH
N
H
SCH3
Ph H
NH2
O
(XV)    (XVI)
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Sally-Ann P.et al.403 synthesised 4,6-Bis[(R-carbamoylethyl)thio]-1-
phenylpyrazolo[3,4- d]pyrimidine and identified as a novel adenosine A1  receptor
antagonist, antagonizing adenosine-stimulated cyclic adenosine monophosphate
generation in guinea pig brain slices.404,405
With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidine derivatives which have
been described in following sections.
SECTION-I SYNTHESIS AND BIOLOGICAL SCREENING OF  4-ARYL-
6-(ISOPROPYL)-5-(3’,4’-DICHLOROPHENYL AMINOCARBONYL)
-1,2,3,4,-TETRAHYDROPYRIMIDINE-2-ONES
SECTION-II SYNTHESIS AND BIOLOGICAL SCREENING OF  4-ARYL-
6-(ISOPROPYL)-5-(3’,4’-DICHLOROPHENYL AMINOCARBONYL)
-1,2,3,4,-TETRAHYDROPYRIMIDINE-2-THIONES
SECTION-III SYNTHESIS AND BIOLOGICAL SCREENING OF  4-ARYL-
6-(ISOPROPYL)-5-(3’,4’-DICHLOROPHENYL AMINOCARBONYL)
2-METHYLTHIO-3,4-DIHYDRO PYRIMIDINES
NH
N
H
SCH3
OH
EtOOC
       (XVII)
N
N
H
SCH3
COO
CF3
PriOOC N
F
(XVIII)
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SECTION-I
SYNTHESIS AND THERAPEUTIC EVALUATION 4-ARYL-6-ISOPROPYL-5-
( 3 ’ , 4 ’ - D I C H L O R O P H E N Y L A M I N O C A R B O N Y L ) - 1 , 2 , 3 , 4 - T E T R A
HYDROPYRIMIDINE-2-ONES
Pyrimidine derivatives have been reported to possess various pharmacological
activities like antibacterial, antifungal, insecticidal etc. In order to achieve better drug
potency, we have synthesise pyrimidine derivatives of type (X) by the condensation of
N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide, urea and aryl aldehydes.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
        Type - (X)                   R=Aryl
NH
N
H
O
CH3
CH3
NH
Cl
Cl
O R
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REACTION SCHEME
Ethylene diamine
toluene
CH3
CH3
O O
O
CH3
NH2
Cl
Cl+
CH3
CH3
O O
NH
Cl
Cl
R
O
+
NH2
O
NH2
Con. HCl  ( 2, 3 drops )
Ethanol
R
NH
N
H
CH3
CH3
O
NH
Cl
Cl
O
        Type - (X)                   R=Aryl
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 Observed
Alkane   C-H str. (asym.) 2931 2975-2950   430
-CH3   C-H str. (sym.) 2879 2880-2860     ,,
  C-H i.p.def. (asym.) 1446 1470-1435     ,,
  C-H o.o.p. def. (sym.) 1388 1390-1370     ,,
Isopropyl                C-H str. 1378 1385-1365               434
Aromatic   C-Hstr. 3110 3090-3030   432
  C=C str. 1517 1540-1480     ,,
Pyrimidine   C=C str. 1595 1580-1520     ,,
  C=N str.
moity   C-H str. 3060 3080-3030     ,,
  C-H i.p. def. 1066 1125-1090     ,,
Amine   -NH str. 3350 3410-3380   433
  -NH def. 1631 1635-1595   434
Cabonyl              -C=O str. 1690 1680-1630     ,,
-C=O str. 1676 1700-1660                 ,,
Type     Ref.        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 4-METHYLPHENYL-6-ISOPROPYL-5-(3’,4’-
D I C H L O R O P H E N Y L ) - A M I N O C A R B O N Y L 1 , 2 , 3 , 4 - T E T R A H Y D R O
PYRIMIDINE-2-ONE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
NH
N
H
O
N
O
H
CH3
CH3
CH3
Cl
Cl
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-1 1.57 3H singlet C-CH3(e)
2 1.78 3H singlet C-CH3(f) -
3 3.87 1H singlet C-CH(g) -
4 5.39 1H singlet Pyrimidine-Hj -
5 7.20-7.22 3H multiplet Ar-H(a+b+c) -
6 7.31-7.37 5H multiplet Ar-M -
7 7.75-7.76 1H doublet Pyrimidine-NHi -
8 8.22 1H singlet Pyrimidine-NHh -
9 8.52 1H singlet Amide-NHd -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-PHENYL-6-ISOPROPYL-5-(3’ ,4’-
D I C H L O R O P H E N Y L ) - A M I N O C A R B O N Y L 1 , 2 , 3 , 4 - T E T R A H Y D R O
PYRIMIDINE-2-ONE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
NH
N
H
O
N
O
H
CH3
CH3
Cl
Cl a
b
c
d
e
f
g
h
i
j
m
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION 4-ARYL-6-ISOPROPYL-5-
( 3 ’ , 4 ’ - D I C H L O R O P H E N Y L A M I N O C A R B O N Y L ) - 1 , 2 , 3 , 4 - T E T R A
HYDROPYRIMIDINE-2-ONES
[A] Synthesis of N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide
 2-Methyl pentanoate 3-one (0.01m, 1.44ml) and 3,4 dichloro aniline (0.01m, 1.61gm)
in 25ml toluene was heated  for 12 hrs using ethylenediamine (1 ml) as catalyst. Methanol
was removed using Dean & Stark azeotropic assembly. The mixture was cooled to room
temperatur, then wash  with sodium bisulphite solution. The layers were settled down,
organic layer was seperated. It was further wash with water and seperate layers. Excess
of solvent was distilled out  and the product was isolated, m.p. 1380C, yield 69%.
TLC System : Ethyl acetate : Hexane (2 : 3)
[B] Synthesis of 4-Phenyl-6-isopropyl-5-(3’,4’ dichlorophenol amino carbonyl)-
1,2,3,4-tetrahydro pyrimidine-2-one.
A mixture of  N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide (2.74gm, 0.01),
urea (0.60gm, 0.01) and benzaldehyde (1.06gm, 0.01) in 15ml of ethanol containing
few drops of concentrated hydrochoric acid was refluxed for 4-5 hrs. The solution was
allowed to stand for 12 hrs at room temperature and the resulting solid mass seperated
was filtered and crystralized from dioxane.m.p. 2210C, yield  40%.
 (C20H19Cl2N3O2)  required; C, (59.42%); H, (4.74%);  N, (10.39%);  found; C,
(60.48%); H, (5.89%);  N, (10.52%).
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly other 4-(aryl)-6-isopropyl-5-(3’,4’ dichlorophenyl amino carbonyl)-
1,2,3,4-tetrahydro pyrimidine-2-one  derivatives were synthesised. The physical data
are recorded in Table No. 10.
[C] Antimicrobial activity of 4-Aryl-6-isopropyl-5-(3’,4’ dichlorophenyl amino
carbonyl)-1,2,3,4-tetrahydro pyrimidine-2-ones.
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No.10.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all the compounds were
moderately active against Gram positive & Gram negative bacterial strains.
In case of Gram positive bacterial strain maximum activity was observed in
compounds bearing R =4-fluorophenyl and 4-nitrophenyl have fairly inhibit the growth
of B. coccus. Almost all the compounds have least active against S. aureus, while the
compounds having R= 4-chlorophenyl and 3-bromophenyl displayed significant activity.
In case of Gram negative bacterial strain, compounds bearing R=4-methoxyphenyl
and 4-methylphenyl  have shown maximum activity against E.aerogenes and
R=4-methoxyphenyl, 4-fluorophenyl and 2-chlorophenyl against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against A. niger, while the compounds
having R=4-methylphenyl and 4-fluorophenyl  have been fairly inhibit the growth of
A. niger and the zone of inhibition is 21mm and 20mm respectively.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
179Dihydro pyrimidines....
SECTION-II
SYNTHESIS AND THERAPEUTIC EVALUATION 4-ARYL-6-ISOPROPYL-5-
( 3 ’ , 4 ’ - D I C H L O R O P H E N Y L A M I N O C A R B O N Y L ) - 1 , 2 , 3 , 4 - T E T R A
HYDROPYRIMIDINE-2-THIONES
Compounds containing thio pyrimidine ring are widely distributed in nature . Many
of these derivatives are reported to possess different biological activities such as
anticancer, calcium channel blockers, diuretics, antitubercular, spermicidal etc. These
valid observation led us to sunthesise pyrimidine thiones of type (XI) by the condensation
of  N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide, thiourea and aryl
aldehydes.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
        Type - (XI)                   R=Aryl
NH
N
H
S
CH3
CH3
NH
Cl
Cl
O R
180Dihydro pyrimidines....
REACTION SCHEME
Ethylene diamine
toluene
CH3
CH3
O O
O
CH3
NH2
Cl
Cl+
CH3
CH3
O O
NH
Cl
Cl
R
O
+
NH2
S
NH2
Con. HCl  ( 2, 3 drops )
R
NH
N
H
CH3
CH3
O
NH
Cl
Cl
S
Ethanol
        Type - (X        Type - (I)                   R=ArylI)
R=Aryl
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 Observed
Alkane C-H str. (asym.) 2921 2975-2950    430
-CH3 C-H str. (sym.) 2877 2880-2860     ,,
C-H def. (asym.) 1476 1470-1435     ,,
C-H def. (sym.) 1396 1390-1370     ,,
Isopropyl -C-H str. 1371 1385-1365    434
Aromatic C-H  str. 3119 3090-3030    432
C=C str. 1528 1540-1480     ,,
C-H i.p. (def) 1094 1125-1090     ,,
C-H o.o.p. (def) 809 835-810     ,,
Pyrimidine C=C str. 1599 1580-1520     ,,
moity C-H str. 3071 3080-3030     ,,
C-H i.p. def. 1056 1125-1090     ,,
Amine -NH str. 3289 3410-3380     433
-NH def. 1618 1635-1595     434
  Amide -C=O str. 1656 1690-1660            ,,
-C=S str. 1297 1300-110     “
 Halide -C-Cl str. 716 700-750     431
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 4-(p-METHYLPHENYL)-6-ISOPROPYL-5-(3’,4’-
D I C H L O R O P H E N Y L ) - A M I N O C A R B O N Y L 1 , 2 , 3 , 4 - T E T R A H Y D R O
PYRIMIDINE-2-THIONE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
0.0
25.0
50.0
75.0
100.0
125.0
150.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 537.1
 697.2
 716.5
 744.5
 809.1
1056.9
1094.5
1297.0
1396.41476.4
1528.5
1599.8
1618.2
1656.7
2877.6
2921.0
3071.4
3119.6
3289.43414.7
NH
N
H
O
N
S
H
CH3
CH3
Cl
Cl
CH3
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1 1.54 3H singlet C-CH3(e)      -
2 1.76 3H singlet C-CH3(f)      -
3 3.78 3H singlet Ar-OCH3      -
4 3.80 1H singlet C-CH(g)      -
5 5.08-5.09 1H doublet        Pyrimidine-Hj      -
6 6.82-6.84 2H doublet Ar-Hkk’ Jkl-9.84
7 7.14-7.17 2H doublet Ar-Hll’ Jlk-9.64
8 7.24-7.26 1H doublet Ar-Hb Jbc-8.36
9 7.51-7.53 1H double Ar-Hc      -
doublet
10 7.892-7.899 1H doublet Ar-Ha Jac-2.44
11 8.30 1H singlet         Pyrimidine-Hi       -
12 8.60 1H singlet         Pyrimidine-Hh       -
13 9.17 1H singlet Amide-Hd       -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-(P-METHOXYLPHENYL)-6-ISOPROPYL-5-
(3’,4’-DICHLOROPHENYL)-AMINOCARBONYL1,2,3,4-TETRAHYDRO
PYRIMIDINE-2-THIONE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION 4-ARYL-6-ISOPROPYL-5-
( 3 ’ , 4 ’ - D I C H L O R O P H E N Y L A M I N O C A R B O N Y L ) - 1 , 2 , 3 , 4 - T E T R A
HYDROPYRIMIDINE-2-THIONES
[A] Synthesis of N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide
See [B] Part-I,Section-I (A)
[B] Synthesis of 4-Phenyl-6-isopropyl-5-(3’,4’ dichlorophenol amino carbonyl)-
1,2,3,4-tetrahydro pyrimidine-2-thione.
A mixture of N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide (2.74gm,
0.01), thiourea (0.76gm, 0.01) and benzaldehyde (1.06gm, 0.01) in 15ml of ethanol
containing few drops of concentrated hydrochloric acid was refluxed for 4-5 hrs. The
solution was allowed to stand for 12 hrs. at room temperature and the resulting solid
mass seperated was filtered and crystralized from dioxane.m.p. 2180C, yield 48%,
(C20H19Cl2N3OS)  required; C, (57.15%); H, (4.56%);  N, (10.00%);  found; C,
(59.21%); H, (4.66%);  N, (10.12%).
TLC System : Ethyl acetate : Hexane (3 : 2)
Similarly other 4-aryl-6-isopropyl-5-(3’,4’ dichlorophenol amino carbonyl)-
1,2,3,4-tetrahydro pyrimidine-2-thione derivatives were synthesised. The physical data
are recorded in Table No.11.
[C] Antimicrobial activity of 4-Aryl-6-isopropyl-5-(3’,4’ dichlorophenyl amino
carbonyl)-1,2,3,4-tetrahydro pyrimidine-2-thiones.
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No. 11.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded that the compounds
bearing R=4-methylphenyl, 3-bromophenyl and 3-hydroxyphenyl have displayed
considerable activity against B. coccus. The compounds having R= 4-methoxyphenyl,
4-fluorophenyl and 2-hydroxyphenyl have shown maximum activity against S. aureus.
In case of Gram negative bacterial strain,the significant activity was displayed by
the compounds bearing R=4-methoxy phenyl  and 3-hydroxyphenyl against E.aerogenes
and R= 4-chlorophenyl and 4-nitrophenyl  against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against  A. niger, while the
compounds having R=4-methoxyphenyl and 2-hydroxyphenyl displayed better activity.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin &antifungal
activity was compared with standard drug viz. greseofulvin.
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SECTION-III
SYNTHESI AND THERAPEUTIC EVALUATION 4-ARYL-6-ISOPROPYL-5-
(3’,4’-DICHLOROPHENYLAMINOCARBONYL)-2-METHYLTHIO-3,4-
DIHYDROPYRIMIDINES
Many thiomethylpyrimidine derivatives are associated with diversified biological
properties. It was thought of interest that, if aminocarbonyl link present at five position
of thiomethyl pyrimidine nucleus, the resulting compounds may possess significant
biological potency. Thiomethyl pyrimidines of type (XII) have been prepared  by the
condensation of N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide, methyl
imidothio carbamate and different aryl aldehydes.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
        Type - (XII)                   R=Aryl
N
N
H
S
CH3
CH3
NH
Cl
Cl
O R
CH3
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REACTION SCHEME
Morpholine, Toluene
gl.acetic acid
+
CH3
CH3
O O
NH
Cl
Cl
R
O
+ NH2
S
NH
CH3
Toluene
R
N
N
H
CH3
CH3
O
NH
Cl
Cl
S
CH3
NaHCO3
CH3
CH3
OO
NH
Cl
Cl
R
        Type - (XII)                   R=Aryl
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IR SPECTRAL STUDIES OF 4-(p-CHLOROPHENYL)-6-ISOPROPYL-5-(3’,4’-
D I C H L O R O P H E N Y L ) - A M I N O C A R B O N Y L - 2 - M E T H Y LT H I O - 3 , 4 -
DIHYDROPYRIMIDINE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2930 2975-2950    430
-CH3 C-H str. (sym.) 2849 2880-2860     ,,
C-H def. (asym.) 1412 1470-1435     ,,
C-H def. (sym.) 1385 1390-1370     ,,
Isopropyl C-H str. 1370 1385-1365    434
Aromatic C-H  str. 3103 3090-3030    431
C=C str. 1526 1540-1480     ,,
C-H i.p. (def) 1091 1125-1090     ,,
C-H o.o.p. (def) 817 835-810     ,,
Pyrimidine C=C str. 1574 1580-1520     ,,
moity C-H str. 3045 3080-3030     ,,
C-H i.p. def. 1056 1125-1090     ,,
-NH str. 3370 3410-3380     433
-NH def. 1589 1635-1595     434
 Amide            -C=O str. 1670 1690-1660            ,,
  Halide C-Cl str. 700 750-700     432
C-S-C str. 659 700-600     “
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
N
N
H
O
N
S
H
CH3
CH3
Cl
Cl
Cl
CH3
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1 1.65 3H singlet C-CH3(e)     -
2 1.87 3H singlet C-CH3(f)     -
3 2.35 3H singlet Ar-CH3     -
4 4.07 1H singlet C-CH(g)     -
5 5.54 1H singlet        Pyrimidine-Hj     -
6 6.97-7.00 2H doublet Ar-Hkk’ Jkl=7.86
7 7.16-7.28 3H multiplet Ar-Hll’+c     -
8 7.43-7.46 1H doublet Ar-Hb Jbc=8.70
9 7.51-7.52 1H doublet Ar-Ha Jca=2.19
10 8.52 1H singlet        Pyrimidine-Hh     -
11 9.54 1H singlet        Pyrimidine-Hd     -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-(P-CHLOROPHENYL)-6-ISOPROPYL-5-
(3’,4’-DICHLOROPHENYL)-AMINOCARBONYL-2-METHYLTHIO-3,4-
DIHYDROPYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
N
N
H
O
N
S
H
CH3
CH3
Cl
Cl
CH3
Cl
a
b
c
d
e
f
g
h
i
j
kk'
ll'
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION 4-ARYL-6-ISOPROPYL-5-
(3’,4’-DICHLOROPHENYLAMINOCARBONYL)-2-METHYLTHIO-3,4-
DIHYDROPYRIMIDINES
[A] Synthesis of N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide
See [B] part-1,section-I(A)
[B] Synthesis of N-(3,4-dichloro phenyl)-2-(4-methoxybenzylidine)-3-(4-isopropyl)-
3-oxopentamide.
 A mixture of  N-(3,4-dichlorophenyl)-3-(4-isopropyl)-3-oxopentamide (2.74gm,
0.01) and anisaldehyde (1.36gm, 0.01) in 25ml of toluene was heated for 14-16 hrs.
using  morpholine (1 ml) as catalyst. Water was removed azeotropically using Dean &
Stark assembly. The mixture was cooled to room temperature and sodium bisulphite
treatment was given. Then it was stirred  for 15 mins., settled down  for 20 mins. The
layers were seperated and organic layer was washed with sodium bisulphite solution,
further stirred for 15 mins. The layers were settled down, organic layer was seperated
out. Excess of the solvent was distilled out and product was isolated, crystalized from
DMF, m.p. 1840C, yield 52%, 2.02 gm. (C20H19Cl2NO3) required; C, (61.24%); H,
(4.88%);  N, (3.57%);  found; C, (61.20%); H, (4.85%);  N, (3.55%).
TLC System : Ethyl acetate : Hexane (1.5 : 3.5).
[C] Synthesis of 4-Methoxyphenyl-6-isopropyl-5-(3’,4’-dichloro phenyl-amino
carbonyl)-2-methylthio-3,4-dihydro pyrimidine.
The sulphate salt of methyl imidothio carbamate (0.015m, 2.80gm) was dissolved
in DMSO, NaHCO3 (2gm) was added  and stirred for 15 mins. Then N-(3,4-dichloro
phenyl)-2-(4-methoxybenzylidine)-3-(4-isopropyl)-3-oxopentamide (0.01m, 3.92gm)
was added and the mixture was heated at 75-800C for 8 hrs. It was then cooled to room
temperature and dumped into water and toluene. Then organic layer was seperated, 5
ml of NH3  solution  and 20 ml of water was added. The mixture was further stirred for
10 mins,organic layer was seperated out and washed  with water. HCl was added till
acidic pH. The material was filtered and further washed with toluene and water.
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Ammonia solution was added till 8-9 pH. Organic layer was seperated. Excess
of solvent was distilled out. The product was isolated and crystalized from DMF, m.p.
1720C, yield 48%, 2.2 gm. (C22H23Cl2N3O2S)  required; C, (56.90%); H, (4.99%);
N, (9.05%);  found; C, (56.95%); H, (5.15%);  N, (9.21%).
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly other 4-aryl-6-isopropyl-5-(3’,4’-dichlorophenyl-amino carbonyl)-2-
methylthio-3,4-dihydro pyrimidine derivatives were synthesised. The physical data are
recorded in Table No.12.
[D] Antimicrobial activity of 4-Aryl-6-isopropyl-5-(3’,4’-dichloro phenyl-amino
carbonyl)-2-methylthio-3,4-dihydro pyrimidines.
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No.12
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all the compounds were
moderately active against Gram positive & Gram negative bacterial strains. In case of
Gram positive bacterial strain maximum activity was observed in compounds bearing
R =4-methylphenyl and 3-hydroxyphenyl have fairly inhibit the growth of B. coccus.
Almost all the compounds have least active against S. aureus, while the compounds
having R=4-methoxyphenyl, 4-fluorophenyl and 2-hydroxyphenyl shown significant
activity.
In case of Gram negative bacterial strain,compounds bearing R=4-methoxyphenyl
and 3-hydroxyphenyl  have shown maximum activity against E.aerogenes and
R=4-chlorophenyl and 4-nitrophenyl give the zone of inhibition is respectively 20mm
and 21mm against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against A.niger, while the compounds
having R=4-methoxyphenyl and 2-hydroxyphenyl shown significant activity.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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MICROWAVE INDUCED SYNTHESIS
INTRODUCTION
Developing chemical compounds with the desired biological properties is time
consuming and expensive consequently, increasing interest is being directed towards
technologies that allow more rapid synthesis and screening of chemical substances to
identify compounds with functional qualities.
Microwave technology has been used in chemistry since the late 1970s,
but it has only been implimented in organic synthesis since the mid-1980s. The slow
uptake of technology has been attributed to its initial lack of controlability and
reproducibility, coupled with a general lack of understanding of the basis of microwave
dielectric heating. However, since the late 1990s, the number of publications related to
MAOS has increased dramatically to a point where it might be assumed that, in a few
years, most chemists will probably use quick bursts of microwave energy to heat and
drive chemical reaction406. As of 2003, many of the pharmaceutical, agrochemical and
biotechnology companies are already using MAOS as a forefront methodology for
library synthesis and lead optimisation as they realise the ability of this enabling
technology to speed chemical reaction.
Two forces are cultivating the current interest in microwaves for synthesis. First
technical advances derived from many years, experience with hardware, software and
reaction vessel design have produced microwave labstations with the performance and
flexibility to meet the need of organic chemistry. Second, the open literature is mature
enough to demonstrate clearly just how effective microwave can be at enhancing
synthetic reaction.
Microwave enhancement can take several forms. Reaction rates can be
accelerated, yield can be improved and reaction pathway can be selectively activated or
suppressed. Not only it microwaves some times able to reduce chemical reaction times
from hours to minutes, but they are also known to reduce side reaction and improve
reproducibility.
Microwaves are form of electromagnetic energy. Microwaves, like all
electromagnatic radiation, have an electrical component as well as magnetic component.
The microwave portion of the electromagnatic spectrum is characterized by wavelengths
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between 1mm and1m, and corresponds to frequencies between 100 and 5000MHz.
Milestone microwave labstations use a specific, fixed frequency of 2450MHz (2.45GHz).
The rapid transfer of energy into the bulk of the reaction mixture is the main
interest being listed, without inertia since only the product is heated and the case of
utilisation. Further more,as the depth of penetration in materials is of the same order of
magnitude as the wavelength, microwaves interact with substance of appreciable
thickness(about 10cm). Those molecules having dipole moment when submitted to an
electric field become alligned. If this field oscillates, the orientation changes at each
alternation. The strong agitation,provided by the reorientation of molecules,in phase with
the electrical field excitation, causes an intense internal heating,upto 100C per second,
when powerful waves are used.
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute
to the heating effect when the conducting particles are in contact with a non conducting
medium, e.g. in heterogenous reactions. It is particularly convenient that qualitatively
the larger the dielecric constant, the greater the coupling with microwaves. Thus solvents
such as water, methanol, DMF, ethyl acetate, chloroform, acetone, acetic acid,
dichloromethane and R-spirit are all heated when irradiated with microwaves.
Non-polar solvents like CCl4, toluene, xylene, diethylether do not couple and therefore
do not heat with microwave irradiation.
It has been reported that the rate of variety of organic reaction such as Diels
Alder407,408, Claisen reaction409,410, Oxidation411-413, Reduction414,
Diacetylation415-417, Esterification418 Hydrolysis of esters419,420, Dobenr
Condensation421, Knoevenagel  condensation422 could be enhanced by microwave
irradiation.
These experiments sometimes needs solvents which faces some problems with
safe operation appeared and sometimes explosion results. Therefore, to solve these
problems solvent free reaction has been developed and to facilitate the scale-up of
preparative runs. Recently, reactions under dry conditions using inorganic reagents are
gaining more attention because of their enhance selectivity and milder conditions than
those associated with conventional homogenous reaction procedures. It shoud be noted
that some of inorganic additives reach temperatures in excess of 10000C very rapidly
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and decomposition of materials may be problematic, therefore some precaution
regarding superheating and associated fire hazards or explosions are taken.
Detail review on “Microwave Assisted Reactions” by S. Caddick423,
involves variety of unusual chemical reactions like,
1. Aromatic Substitution Reactions
2. Alkane Functionalisation
3. Catalytic Transfer Hydrogenation
4. Oxime Synthesis
5. Radical Reactions
6. Peptide Synthesis
7. Rearrangements
8. Pericyclic Reactions
The success stories of MAOS in the drug discovery process are main fold and
have been documented in several recent articles involving both target and lead
discovery, lead optimisation and drug development with the most recent advances in
reactor technologies,such as continuous flow microwave systems. Knowing all these
process chemist are now taking MAOS seriously, and also gaining importances due to
advantages and environmentally friendly process they offer.
In view of the pronounced biological activities of triazoles and 1,3,4-thiadiazoles,
the synthesis of new derivatives which contain above mentioned pharmacologically   active
nuclei have been undertaken. A comparative study for synthesis of dihydro 1,3,4-
thiadiazole using conventional method and microwave irradiation has been made in order
to study the rate of reaction period and yield  which have been described as under.
SECTION-I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
(o,p-DICHLOROPHENYL)-5,6-DIHYDRO-6-ARYL-[1,2,4]-
TRIAZOLO[3,4-b][1,3,4]-THIADIAZOLES  BY CONVENTIONAL
METHOD
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
(o,p-DICHLOROPHENYL)-5,6-DIHYDRO-6-ARYL-[1,2,4]-
TRIAZOLO[3,4-b][1,3,4]-THIADIAZOLES BY MICROWAVE
METHOD
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(o,p -DICHLORO
P H E N Y L ) - 5 , 6 - D I H Y D R O - 6 - A RY L - [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b] [1,3,4]-
THIADIAZOLES BY CONVENTIONAL METHOD
Looking to the biological properties of dihydrothiadiazoles, it was considered
worthwhile to synthesise different types of dihydrothiadiazole derivatives of type (XIII),
prepared by the condensation of 3-mercapto-4,N-amino-5-o,p-dichlorophenyl-1,2,4-
triazole with different aromatic aldehydes in presence of  p-toluenesulphonic acid.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N N
N
N
H
S
R
ClCl
Type (XIII)     R = Aryl
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N N
N
NH2
SH
Cl
Cl
O
NH NH2
Cl
Cl
O
NH NH
S
SKCl
Cl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
N
H
S
R
Cl
Cl
R-CHO
p-TsOH
DMF
REACTION SCHEME
        Type - (XIII)                   R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF  3-(o,p-DICHLOROPHENYL)-5,6-DIHYDRO-6-(p -
ANISYL)- [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2931 2975-2950 430
-CH3 C-H str. (sym.) 2840 2880-2860 “
C-H i.p.def. (asym.) 1474 1470-1435 “
C-H o.o.p. def. (sym.) 1357 1390-1370 “
Aromatic C-H  str. 3091 3080-3030 431
C=C str. 1564 1585-1480 “
C-H i.p. def. 1108 1125-1090 “
C-H o.o.p. def   828   835-810 “
Triazole C=N str. 1600 1612-1593 430
moiety C-N str. 1265 1350-1200 434
N-N str. 1022 1050-1010 430
Thiadiazole N-H str. 3440 3450-3200 432
N-H def. 1600 1650-1580 “
                                               (overlapped)
C-S-C str.  677                    720-570 431
Ether C-O-C str. (asym.) 1265 1275-1200 430
                                               (overlapped)
C-O-C str. (sym.) 1022 1075-1020 “
                                     (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 499.5
 631.6
 677.0
 730.0
 828.4
 866.0
 929.6
1022.2
1108.0
1166.9
1265.2
1357.8
1422.4
1474.5
1564.2
1600.8
2840.0
2931.6
3091.7
3440.8
N N
N
N
H
S
O
CH3
Cl
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 3-(o,p-DICHLOROPHENYL)-5,6-DIHYDRO-6-(p-
ANISYL)- [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.85 3H singlet Ar-OCH3                     -
2. 6.92-6.94 2H doublet Ar-Hdd’ Jde-8.8
3. 7.66-7.69 2H doublet Ar-Hee’ Jed-8.8
4. 7.38-7.41 1H double Ar-Hb Jbc-1.90
doublet Jba-8.50
5. 7.49-7.51 1H doublet Ar-Ha Jab-9.23
6. 7.52-7.53 1H doublet Ar-Hc Jcb-1.92
7. 10.04 1H singlet -CHf                      -
8. 11.3 1H singlet -NHg         -
N N
N
N
H
S
O
CH3
Cl
Cl a
b
c
d
e
f d'
e'
g
206Dihydro thiadizoles....
EXPANDED AROMATIC REGION
N N
N
N
H
S
O
CH3
Cl
Cl a
b
c
d
e
f d'
e'
g
Cl
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(o,p-DICHLORO
P H E N Y L ) - 5 , 6 - D I H Y D R O - 6 - A RY L - [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b][1,3,4]-
THIADIAZOLES BY MICROWAVE METHOD
As a part of our research programme towards the non traditional approach to
the experimental set up of organic reactions, the concept of “Microwave induced
Organic Reaction Enhancement” (MORE) chemistry has been utilised for rapid
and efficient synthesis of some dihydrothiadiazoles, which is described as under.
The synthesis was carried out by irradiating condensation of 3-Mercapto-4,N-amino-
5-o,p-dichlorophenyl-1,2,4-triazole with different aromatic aldehydes in the presence
of  p-toluenesulphonic acid.
Various preparations of the dihydrothiadiazoles by microwave irradiations are
available in literature.424-429
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation
source and data are compared in terms of yield and reaction period have been cited in
Table No. 13a.
N N
N
N
H
S
Cl
R
Cl
N N
N
NH2
SH
ClCl
R-CHO, P-Ts-OH
DMF
microwave irradiation 
8-10 mins.
Type (XIII)    R = Aryl
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TABLE NO. 13a   :  COMPARISION OF CONVENTIONAL METHOD AND
MICROWAVE INDUCED SYNTHESIS OF 3-(o,p-DICHLORO
PHENYL)-5,6-DIHYDRO-6-ARYL-[1,2,4]-TRIAZOLO
` [3,4-b][1,3,4]-THIADIAZOLES
Comp.
  No.
R Thermal Microwave M. P.
 oCReaction
Period (hrs.)
Yield
  %
Reaction
Period (min.)
  13a 4-OCH3-C6H4- 12 68 10 79 106
13b 4-CH3-C6H4- 13 62 11 74 180
13c 4-OH-C6H4- 11 60   8 76 224
13d 4-Cl-C6H4- 14 58 10 65 210
13e 3,4-(OCH3)2-C6H3- 12 65 10 70 189
13f 4-F-C6H4- 14 69 12 75 140
13g 9-C14H9- 13 70 11 77 145
13h 2-Cl-C6H4- 14 48 10 64 200
13i 2-NO2-C6H4- 13 62 11 78       160
13j 3-OH-C6H4- 11 66  8 76 186
13k 2,4-(Cl)2-C6H3- 14 72 12 84 195
13l 2-OH-C6H4- 11 59   9 68 170
Yield
  %
CONCLUSION
We have demonstrated a rapid and general synthesis of 1,3,4-dihydro thiadiazoles
using a variety of aromatic aldehydes with heating in a microwave oven which can be
considered as a step towards Green Chemistry. Consequently, reactions exhibit cleaner
products and more facile work-up procedures. The method affords high yields of the
desired products in remarkably short reaction times   decreased to 8-10 min. from 10-
14 hrs. and improve reproducibility. The reaction conditions are sufficiently mild to be
employed for the construction of the heterocyclic thiadiazole system and suitable for high
throughput synthesis of the compounds.
210Dihydro thiadizoles....
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(o,p -DICHLORO
P H E N Y L ) - 5 , 6 - D I H Y D R O - 6 - A RY L - [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b][1,3,4]-
THIADIAZOLES
(A) Synthesis of Potassium(o, p-dichlorophenyl) dithiocarbamate
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-(o, p-dichlorophenyl)-1,2,4-triazole
See [A] Part-I, Section-I (D).
SECTION-I
(A) Synthesis of  3-(o, p-Dichlorophenyl)-5,6-dihydro-6-(p-anisyl)-[1,2,4]-triazolo
[3,4-b][1,3,4]-thiadiazole by conventional method.
A mixture of 3-mercapto-4,N-amino-5-(o, p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01 M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene
sulphonic acid (50 mg) was refluxed for 12 hrs. The reaction mixture was poured onto
crushed ice. The product was isolated and crystallised from ethanol. Yield 68%, m.p.
106oC, (C16H12Cl2N4OS : Required : C, 50.67; H, 3.19; N, 14.77; Found : C, 50.75;
H, 3.25; N, 14.85%).
TLC solvent system : Acetone : Benzene (4 : 6).
Similarly  other derivatives were synthesised. The physical data are recorded in
Table No. 13.
(B) Antimicrobial activity of 3-(o, p-Dichlorophenyl)-5,6-dihydro-6-aryl-[1,2,4]-
triazolo-[3,4-b][1,3,4]-thiadiazoles.
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 13.
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SECTION - II
(A) Synthesis of 3-(o, p-dichlorophenyl)-5,6-dihydro-6-(p-anisyl)-[1,2,4]-
triazolo[3,4-b][1,3,4]-thiadiazoles by microwave method.
A mixture of 3-mercapto-4,N-amino-5-(o, p-dichlorophenyl)-1,2,4-triazole
(2.60 g, 0.01 M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene
sulphonic acid (50 mg) was irradiated in a microwave oven for 8-10 min at 280 watts.
The contents were cooled and poured onto crushed ice. The product was isolated and
crystallised from ethanol. Yield 79%, m.p. 106oC.
Similarly other derivatives have been synthesised.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
 From the experimental data it has been concluded that all the thiadiazoles  of
type (XIII) were mild to moderately active against different strains of Gram positive and
Gram negative bacteria.
It  was observed that the compound show good activity against  Gram positive
bacteria,maximum activity was observed  in compounds bearing R=4-methylphenyl,
4-fluorophenyl and 2-nitrophenyl against B.coccus. Compounds bearing R=3-
hydroxyphenyl active against S.aureus. The significant activity was observed in
compounds bearing R=4-fluorophenyl and 2-chlorophenyl against E.aerogenes and
Almost all the compounds were found inactive against P.aeruginosa, while the
compounds bearing R=4-hydroxyphenyl and 2,4-dichlorophenyl fairly inhibit the growth
of P.aeruginosa.
ANTIFUNGAL ACTIVITY
It has been found that all the compounds exhibited mild activity against A.niger
and compounds bearing R=3,4-dimethoxyphenyl and 3-nitrophenyl which showed good
activity against A.niger.
The antibacterial activity was compared with standard drugs viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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